var title_f19_3_19504="Palpation of prepatellar bursa";
var content_f19_3_19504=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F56055&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F56055&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Palpation of the prepatellar bursa",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 349px; height: 289px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEhAV0DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD0i3l+1x4hgxKTll/hqXT9RFvPKL/fb7vuxqOnvzVaXUbuNIDpPzW5XD8dDmo9X1TTT5Es83mTpjcABljSvbUwNq8ntJo1P2m5kEg5QBevbNebX1/DYz3TQeYl6G+RiONvf8a7WLX9Kiktzb7XUDcFP96uG8QahfpJJtsInVH3MTndtJJxUyloOKLGn3OqHTINWOqPaStL5crELhgTww46AdapeIIRot8DeX6S2s2JWZCNkmec+tY2q68hsrq3sImMTBFWN+ChYfNwPeuPvWEc8aM0juiD5WYnHHuaylNJGsYXZc1nUYJ713WTZCOYwev0rCadZ5iWZIv9od6Y8rO8jy9DwBWVqWqJbWrZGcdu9Yayeh0KKSH6lcQx5MsqoOgPY1z91rSCGWKBzlRgMehPtVG/1mS8t2heMbf4TnkVlAE9K6IUktZESnfYfNK80rSSNuduSaaqkmpFiPFWEiyOBWrkkSotjIoRgHqasRxdMDIqxHCAvNWEUenWueVQ2jAgWAbVGMU9oPX9KshWJwBzUgVTw3UVi5s2VMz/ALMSehpPsXcg1qoF6BcipRGzEYXj0pOs0XGjcxVsMt0OKnj04YPHI7GtlLSR3GBgVv6P4YutSnSKCNjk+lZTxTWlzeGFW7OTt7IKOQRVk2wXsSK9r0n4RvPZK07EOR6DA/WqOrfCu9trcyQDzAD0AH+NZTqT3aKjGk3ZM8bktxzkAg1VmskboOK9Nufh9q0QG61cZ9v/AK9ZVx4T1CIHdbSYz/doWI5RuhF7annEtjxkZ/Cq7WpU+1eg3Xhm/jhMptXMY77awLiyKZymD7iumGLuc88J2OZa37iozCfStqS3IbOKqtF1wK6o1bnHKjYzPLIppUir5Tr7VG0YOa0UzNwYllfyWqlAA0bclTXTWGrMnliNgCR+VclJGVximrI6AhWIB64pTpxmJScT1bSrxJIpGDDzAOtbthqZsHW4sXLS258wrJjBI+n1rzHQbsmFVHDL1JPWumilk2bYFO6Uba5LOLsaNKSPWfCusQalqUlx4gghee5G55MkLHgcVu3kU8smNMvkkgZW29MgD1/SvMoruwfwjHHPIq6nDKo2A4LL3NdD4blijg3LfrDCcB9zcnIGa6Iyuc7VjtIp57NMS+U5jC4yeTkVUutaeZXSKwLydBweprk9TuNQicXlvcblBKRSZ7dP8K0LXxBdwW/mz27Mu0qxI5JNPm1sKxJBcWxkVJ98MqvggD7xPX8utPvVuDK62t8JEMhVUbHz479KpXetLdwJHDZbEfbG8hGNuOCf1pz2dpbMwS9DlSVj55A7Glvohk3n3I3QQ222Uty46H6VHdyPBbGWe1Yyg7Qx6UWN1cpFKI50nkRcED+Hmqkt7dCVbeCOSQMMtkcGm3YEOupYbpvIkkEVrs3B/U+1ZmrWzl4jpU25CvzhOQDmreuX8cFkouLPORsYe/XNcrNquyZ3sp2sonOfLHJ/HNS9RnuF/qkkFitrZQhYZIyysCcDnHJ9ayrI6fpOnC+1qSO6l3YZUOcE9v1rJsNTA8PajpF2JRqF1J/o67TjGP73bnNcNrsR067NteuzNFIPMQOSM/5NaSn1RCi9jtT4l0NbM3CgNPJMCYlzwvNXZvF9rJHexxQOFmCbQ68ghcV5bFcWspnJjMB6xxhc549a1JfE9oXgW5sg4jiaNowSpfOOcis/aW6l+zCd57u/uDGhVlUSNGoyQFHWsK6ujJL5+cvIMH2p13rU0rRiEFFAYAjIIU9VJ71iajqkdlGGkB6jgCsfi0RulbVhqV6ltbO7MjOv8O7muEurmS5lZ5GOSemal1S8+23jzBdqnotVAM9K6qdPkXmZylcAM1at4u/rSQRZ7VoQL26UTnZDjHXUhWLocVajjCj5utKqjoOtShRjnOK55SubRQINwwBzUscYA+bqKaGCninqTWTNoq5IMdqkRVznvRHEXYGtCzsJJ2wiEmsZySOmFO5VRct8oxWrp2mz3cipGpZie1dLoXg6e4ljZ1yCeemOtep+HPBYs7pJtgUD6Y61jJynsbrkp77nO+DvhxJM8c98AsXXBxzzXsegeHdNsIlaOCNX6dB1qzYwmHauQB7c1pqrFAWbkHPyrWtOnGGpy1akp7snjhKw5RAFzjHSpDBC0Sp5O4jkqBnNCeZIQNjEZxgdqVIlhcrtfzv7yknbW/Mc7itiC4ht1cnyFC4wVcDIrFvdOs2iI8lMk5Pyj/CtiUgsQyuSeuR1rPu3O8ncV9V2/wBamUilAxrjSrZ4mjaBPf5R/hXnXi74c2t5G8tooSX0AHNepSuO2TnuOc1TuG3HByB6EYrCdpbmsXKDvE+U/EXha+0tz5sRK+oxXJyxlCdwr691nTra+iaOZFbPcgV474v+HxQNNY4YHtxThNw80U3GpvozxuVQQcioZI+OOmOa0tRs5LSZopl2svWqJyFx+FdsJXV0ck4uLsypKMcHrVaRPSrsgyenFMeIEHrW8ZWMJIisrkwyKGPy56+ldhp13KiI/O9TlB61xMiEGr+nai8R2vl2/hOTxSq0+ZXQou2jPQUurJ1Ml0MSCJgoHZv85qWzvLW6mjtJD5S95NxxXJ27maQZG6TaTnsKvWszKrB0Xb0yOc1glYbVz03TbXzlc2+oeZBafMgbGGPenz+Ir61iMbxRyu2XG0Z46j8q5WSMWemwzxTFBJ1G41Gkl1Db/aoywV+Azc5x169qtNozaOns9a1GzEc1zaeZEA0mNvALDqau2D6bcR+fMX3OoZnPTf3rnLfxFdLb/Z9Qty1vclWfjHyKcrj261uapqccmlHy7BobJ5WYuy7flP3cH60+bo2KxPE1hNdNHZO0L7toYk/N9atTXVzbtJb2apNIPlMh4IrMtG0o6UVabypgNxIHzH0wKybuBmsRcRXax3IP3Xl2kii7toFjR1uTUpCIbm3SMRjO/ORXHagltmJrmaNLgqfMXd0Oa0r0zf2c90188uBzGScn6etcxHLaEE3od5icnI6U0+rGeqa34iltNZt9btAj3at5scbp8uMbcfzrj9Wup72d768ULJcneUB3Y/GnRJdai4SWRPLhXkhdvf8AWkt5oUvLZpkaa3Q8xj5eOe9JybYoqxBtWWUNtwAMjccUyd1373jXzAQBjofxqfWdVjurkrFEEhX7gxz+JrGmclcMTis9b3N0Nvr2OOFyRsIOW9APrXC6jePdzFiTsHCir+u3wmzDGfkU+nXrWLXRShZXZE5X0QVPAm5gTmo41yatxjGAAc1pJ2FFXJlAUE9xU8S+Zx0AqNIuhb8anPAwK5pM12JVdVGFGfejJZuOn1pqbQAepp+zJ+WstEaRVxyLzlqu2kDyuAg68CpNOsmndM8DPUmvQ/DGgROyPtOR3JrCc+iOqEUldmbpXhR5o0JDF+pweK9J8J+Eo4Skk2N3ocf4Vr6dZpFEo+4O7E/0robMIqZjU4/vN3/wrJwSd2U6smrIv2dlBAAFQLjuO9aqsEx1c+lZKSKG+983oOa0bYu+Ai4z3PNXz30M1Euo8jAHCKufXmrm5yq4kycfdC1QMYjAeVsAc1Wj1iWaRktLZzjgMy7Ofxql5jt2N+3EzswkQr/uvViNn87aZCgXvtyaw7e61RV3TWQAPpMOa17S5Zx5rWzI/cFs5rRIiSC5jLgg3TFuw8rGKzrlCGLH5uOT0rVlBA3bSvH3jVN4fvEsfUqehpSQ4vuZE8aFjk7R2welZ08T54dXB7f/AF6154yoKPg/hWXcABsFSPpWEjRGTdKc9Cp/Osy5kPR0Oex7VtXBBPBz7VRlUEFTyPeoWmwnqjznxv4VttUtXkjQLcY4I78fSvCtTsprKeSGdSrKcV9OXx8okYyufyrz/wAe+H4tTtGlgGJ1HBB68VtCpyu5DjfRniZGW6Y/GgjnParF3bPbXBikUhhxg1XzzXanfVHLKLTsRugKdKq/NE+5OGHrzV3qOlQyJkVpGRnKNxlreSRuodyEBycda37DUWMUrRsogztIZcn8K5l04yKYCVIIPTmrlTUiE2jsJbiGWTBM2zjAJPHrV9NRnk6XA8qIY5HH0xXJ2t+zBvOkA9wOorTguLSaVFDEnsAcD8axcGnYq6e51trqF/cPvmni2yqsQXygfk7cdsAmtqz17UdNCWAdLywjLKiSRZ4x19x6Vw0Nz9lcGCRXTeQe56/oKm+23Uk0kiSqqngjA+VfQVCb6CaOuv8AUZL+0ijgtYA8PRsgMwqCTXJLeRZ7ayCPs2OJk8wH6E9K5yMztMkkDYO3nv8A/qqxqmsXVxpqWM6L8h4ZRg496pa2E0MF6Hv/AD5ICGxkqrHb19KyPENx/al9vdBbrGNqoh7e571Zt4mOGMmMj7veoLqOOSZjIGU/zq07MR213HshUPMEy2CinkcVjF5GwEkwi8DjtVeRWZwZG3SEcg1IhwMKcqB0qLJalIaEzkseT61ka3e+XiGA5fuR2rVuZtkTEcmuengZyx4yeSaI+Zo9jAnO5i1R1Yu1AY7e3eoo13HJrpT0MnuSwox6dKuRptxUcY7DrU6A52tWMpGsVZDzxyaVTn6CmkdRTlAFZdBpXZIg4zj8K29E09rhg7A84wOao6baSTSLtVm5Ar0fQtOW3jTzSFbA+VRXNVqW0OunCyux2jaVDEwM4/4CM122kK+0eVGFQf3ulZ1pau5DFBGnpjLN+NbUVv5aj7W5VCPljDcn6msE2zVo0Yb+GJivNxMPTov0rXs2uLwKZf3Senc/4Vi2URLGSCNIoV6yEdB7D1rXS7SLaz7vmxtA5Z/8PxpXvuFux0VtHEgAVPmx+P51pwbhgZxn061mWZkYAhAnGdvetSAk4OKtMVi5HEC6lk3ehNXo0UkFhkDse1VY26Bzge1WkdG6sQO9bRVjOVy0ip5gUqfrmrzROI9w2YP3RVNdrJwxJPI5qVG3RjzJkQpyoIrePmZST3G3WWz5rbSOi4rPu2+QFuT61dubndtDMpKjrWbc/KCCeDyOetZz1Kgn1MXVIpLmPEchjZTkMKxZ5r21X9+omiH8SjBrdmYcgMcjqKqTLuXPeuduxvaxhC6huPmhbPqvQiqVw56k/SrWp6WJGEtvJ5FyOhXofrWX5k77lnh8qZeueVb39qiyRW5UuH4Bf86xdRxESxX5T1xWleBhkn7p6j0qjdBRGFY7kP3SaS1JaPOfHHh9bpGurYZcDPGa8xkjMchRhgg171MgYPHINrY4HrXl/izSTFdNIi4yT2NdFCrbRmNSNzku1Mx0xU8kbLng1EBnPB6V2JnM1YhkjGTUDpnpV5kHcdqidOMirjIhxKBUjtRG5RsirRTJqu6Fa1UrkNWLdtdfvlAwu44JPatZd6OckbemAc5rmyMVLDLKjZQnPSplBMEzrbO7ey/fxANnjaeavWd+VZpjGru3BB7fSucsrtPMVCjHj5s1r2hi8wGIkqexrGSsNamrbW8cl2WiB2/Q1Je2++6kEce9VOAQM9qu6NBeTXEcNmi+a+ADjIHvXoum6ZZaXbLA6rJL1d26sfxpatiPJhNGFyckZ+8Oq04uuM9f9oGqzMyjC/L9P61WeZ1z8nPXApt3ehS0LFy28bcj6VQvUCwGRWA9VPUVPu3gGUN83TFZ97KZCQWIHTBpRV2U5aGHffKwATaDz9ajhBwT2qxqBXaOpfuT+lMt1yF4rdP3SFuWIVABbHNSA8jFAxjpxS98n0rFu5qh2MZycGr2n2b3DgBc1BZwNPIAoJJOK77w9paRlC6FpMjC46VhVnyo3pQ6sn0TSjFHHuIhiGMtg5au98M6YkilhHgerdT9ai0qzRXVp0Qu33IlHX6+1dNbwFlESqZX/uAfItcel7s6L6WHrbQxjEfzSdCw7VMujkKZ7pRHGOdp5LfX1q7FGtmBwpm6Bf7v0pzIQhnlYPKAduegbsB71WrEtNjMvpY7WIS3TlUA+RTyFHqQOv4Ve8PxXFxH9pFvJGX6Sy9SPb0B96t6bpERdLu9UTXGcoGHCZ7/AFrdJLNl3OTQ4lX6C2cBXhic981qKojXgjJ/SqMRUc5H41Os4Axwc1cUkJ7lqORhwHHPrUyyJuBZgvHYfzrNMuD8pYEdsj9Kcl/tAYsevAarTEzZjlCkbSAvZm5watWzi4Gx7YyHsUIH8659NUJfYpiy3cg5H0qUXuMPJ5ar/efpn8KuM7ESiaV7tJdHhEMvQY61mzZG0usoQjqzAintq0k2f9GVkA+9D39+arPettI8qYKeccZqZOLeg4ppalZ8F2PBHTiq03DsoPI7E5oe4ZmJckn+61UmkVXYgDHoO1Yb7G1r7jZiQeVIHrWddgEnbn6Gr0kvyjkqDVC4+bk/nStroKxi6iwAwVJUcEjqlZN15aOIy2VI5H/s1bV2khbknjp71g3YV8RvgEH5D6e1JoGiheQeahQnMifdbvisPVrD7TETIgYLwRWrMzwzY/iHDKeuKbdfMfMQnDDBHqKhOzIaPNtZ0YIhaMZPoK5Z7dldlIwR7V6xf2AuHCgEEdAe1c9e6OXkclRzyeO/rW9Os1uZygmcKsbE52nFMkQ4PXiu0ttCBYHGQfbrT7nw8skZKDDemK3VdGTpHBlePb2qIKCOa2L3TJ4i3ykEe1ZzIVPIPvXRGaexnKDRReLrii3aONv3wY49DVx054NVJU4rZSurMxasbFiIJwCjFH9Qa6GzsrdMMzliOfvda4CN2ifKEg1p2d++R8xBHvWdSm7aAmeueHL+006B2ym0jGO4+lF34kleX5FEiDp5hBA+ntXnUN27jGT+fWrsUuVy24+4rNXWg2upakDbeT700wBflYbpD92p41BYLuwPU0jAvKzggelJxsyr3KE8RjkAbJPcelUbsbow2AEB5HetO6ch9zZcrWdIZAGZkALdM9KuJLMTUhH5SttbzCR8x6Y5ptsP3QNN1FslQDkg8inwcxIPatX8IR3JlGakiUs2O1Rrwf0rSsIN7gDp61hN2RtBXZu+GrHLh8ck+nTmvStFsm3/AC8L/E5H8q5XQrc7VjXC+uOvWu90mMQ48w/u1Oa4ZO7OtbGxp9rGrlo1G3HzSt1P0rYt7hj8kChR03Gs+Jo5CuRxjhB2HvV2ANkHGFzwBSemwLXcvW1pHHIZJCXc8kmrYhWeaOSQ4jj+5H2+pqJ+FXcAvov+NPtpWeYgDihabFpX1ZtfeQccDp6UMM9Ax9KVOYQg4H65pq+YTgjIXvVWsCZHJJs5dl49ajM6SkFZFB9M0+ZCCW8kHPrVE2c8ykpE2CemKTZSVy1MJtuUdCM+vNNW7dHBmhZlHYVSNs1uQ6xNtJ6qSQPrTmkiwGlRg2e/ehSBxNWO9aMBvIlnIPGQOaqT3c/mnyLaVFb+8OBTbS4RwUigZH7Z6EVZjE5lKywbo89B1xVc19mTy2ewjXV5bR+Z5CO5IO0ZzSRajJcF3lgbcOWPoKvHT2wHHmggZCgAiq8sLQufOEiI/UhRmk+ZehPuvoVZZgX3RNLGp6EgYNV3f5vmO8mpp2WH5EnzAAccDIqsTGVPlMHBH5Ubmi2I5gpG1eh6g1VkxjHT2p+VjGeQx/Kqssp5JIKmpSsBn3jFUKDlcn8KwribaAxAbaea37qReAR07+tczOr29wyy/wCplYsmexI5H0xTa7Et9yqxFzOWIByPlNRrlC6Tdz19KMeVIBEeDyuaeWJG5huJ71nb7yWVnUySAEYYd6geMY2yKCPX1rQiK7iOuOmajxuBOMqTxkVm1ruCZUhgiAUAAN9KbNCASAo/KrgGUyF6cfSq9wwIHUEVaYctzEu7GNywKjn2rn73w6HUmIY/CuzePJyBzio/K2gnsK1jOzRDieT6lpk1oxyhx9Ky3HHTAFeq6lZx3IKsowfauF1LSmhlcBeOorqpVb7mEodjmJVwSaYpIYY61cuI9rEMDxVP7rccEV3Rd0crVmbVhmTaNxz6VrIoVfmZs1kadfqchgqvjr61swzQtGMlSR1LnBNc9RMadjYjnW1QLMGKkcYGarSTwynCIygDORSicF9/miV3G0gjG0VFcTxKAiou4feKng0uuo0VpwSoxyxPJzxVO6AI+5kdMgk81Ymf90SAS3ZPSs+VNxXczZzk9sU4ruDZmXsIRVAyG7g9qktx8impL1sqxIz2zTIP9UM4B9Ktv3RLcmQAv0rotHjXg5wc1zsf3ga39JkKSAKuT79K56q0N6b1O60SPaSy5C+p69a7OyP3EjI6ZLHtXE6KX+7n5m7notdZZSpFAqITz8xJ9Pf0riXmdR0llmScLGuIxySOre1bgQRKHbOR2HNYdhKyxKyDr2HU1rrLvkhjzlure1XFXE2T3Dt5CsyHeelGnFlbJ+8eTT73KJ13ZHBqpah5mKudoHGFps0jsdDDNGxX5t2TyF559KvTRqqLkGLd0LGueg1A2xMdrAzgnl8ZORVu3m2t5ly03nNkeUF3cevtSvcfKzTAmjdXjkjKnrvbAFXY5CQTLMiqP+eQ3CqMFwzJhR5WOBuGc/nU8cUcn7xJh5i/eXGAaab6Ca7lyW2tpl+U+ZlQMgfz9KBbCFT5kUUkeNysOT9KzX1SFCy2jGZh94FdgU+xHWq41W4k8xkhvpNoDgfZsKMnGBzzWlu+grNmy1pYTAGWMA9ih5x71Kmn24jx9rAUfdzj9ar2GpSxwiSfR22SffKMWcH12+lWrXWbKWZYyksD9kmh2nP49aXKhNtdyWOCWNZBDIpHbJ4qvdSt5Y3htqsMrsBXPua0+J2G2csBzs2YA/Gsm7EikhWZUJwQFzk0STQo2bMnUXDvgR5Dd1Xj8aw7u33MzRxPG2MfL0NbmoR+RK2VlSQAfIRwfxrImbzMlXOepTPIP0rN6vU1W2hlSXh4gwzMB93HNVbiRUB2jJ7q3GK1rmSbgGJJWA642ms2b/SIyJ4xDIDwUO7NKw7mbNOQB5wKrn5Swxn6etYOv5ksnb5gA2V29q27mCPYwKEg9Tu3FT7jtWJrDiC1cKoPy4ZS38qTuS7XKsLx3EayKeo6HoDU6RshPmAbW6Ec1U0vb9ht5F5zGCQB0GTWoEeRcLgnHHuKLXE9CmY+DuPPYinMoLEDjjNTq3yn5CccYxTiql1BQjI6Coa0JRXYDov057fWqkkR5LCtGWMI3U5HQ4zuFVmb5yT1/SlYpMomMjkGqs7McdPcVfbknA69KpzRkE55IprR6CsZs2QxPYDpWZPCtwxJAIxzWnc/Kh4yvf61UiTlip7cjtVwbQmkcLrmneWzMnbmuamXBr0LUYw+8HgVxmq23lMSOma9ChUvozjqw6mekbNytTJcSx5BP51fsofMjHPbJxU72IZu/HtW7kuphY6PbFDkYHnf3qqXCiMZSRHbtgCnrMvOVOD0J61XuXjGCABnpisrNMExrSqhx83mHrxVWU7/ALp+ZuoIqVnCr8xy1QSzKi+9NaAVbmMKmcdvXpUUfCjNR3txuB4PNSpyBjrgU3ohokT7wNbGmyoHG48msdQ270qxCwEg7VlJXNIOzO90+XCqMlVbr9O1dVpFx5/3x8p+bA/j9q80t7piuA33uPwrr/DV4Qyg9c/lXDOLTudkXoek6c5QA4zIemOmK1tMnD3sq7ThV4PvXN6ZcByCD0rpNIXy45H6s7f0q4+RL8zYuI/OjxnHHaqvlRbgI1eQgc4Yr+tW4CDGQx/AUoZVjfajKP1/KkaR0H28aRKu+QJnkRqcnNW4YiTvmJQ54AO4/nWTHG7PFJHGfMZsAsen1Fb1mshJMmN4JDAr0prUp6alpHlRB8qCMc7nrNuDe6tM8VtAIrU4DzDj8q0ntWvZEifJhUZODjNakAMarDCm2MdEzWqVjNPXQp6foVpAUUxs0m0YO4/N+Fa/lSRIPIykYOACSabGjKVdid2euelWTuZD1weozRe5drMjiCyt+8dw/U7TTpoI7h9xjSTt842sB9akt1SNQzjDevtUwkEoDBeF9utUkTLfQy20iGNxcWTzxFvvbssCfT2pjq5h2Mu3n72c7q1JVfYql2C4yBtIGKzrhtqMFJIWlJIlNvcw79z5kj7GAHGHbdz+NZMkHmyfeQS4+ma1pijnLliM5bPc1RkiUSfMtYPzNdtjNeEQbtwJk7HdkVWmhMsWXZd3bbWp5RMg3D5QfrUVzbBGJ24OM4FIVzm5UeOB2wBKfvLjO4fWuM1lPtMg5wg+XGeceld/codhJJ5GMY6Vy+pWhTLBQQTn6GlJaDT1MzTIktlWNQREowM84H9avpCFfehbb61Bbu2/7uV+79BWnAgAKjOO1KFraDl5lUkBcrnPQ8VEyP2yT1q5MNseMc/lTHJlKleoGeKtpEpFG4wIR155B9KqEE5AOc+o61ac5U9eDgioXAJz09Kye9ykiucEcjBqrMeQDyKuSLjlqryA9RzS8gsjPnQAHjIrJkHlo20Haa3JmAOD3rIu2+Ur+GK0WojGukBjHOT71halAJIWBGcjiuhnXKntWReYUY9a6IaWOeSOZ05tkpjLYAPatmDBTluntWBe/ub/ACOFNaUUw2811yjexx7M0ZEYj5zjPamR2Xl4Z87m5we1SxwNGwM4LSkZz2WnFj5mfMyfQjpU3toJIb9lUtjOTjmoJ7aPZ0GamaYjPI56nFVp58jHQfXFSk7juYWoxBJ4wOQf8atkYbAHTNULufzroEHKqQBWiRjI9TWstErgh0Y3DjrUojIGWyG96S2UE/NkD2qyYpJG74HSsW1expFXDT3PnYf6Cuo0aUidgH+Yc/X3rk41CXGGfnqa0LS8aF45BypGADzWNWN1dGtN2ep6voN4vy/MOevt7V3enTqYgdwCnv3rw7SNRdbtV+7kjg9vevTdBuJM/eDtxgMaxg7M3kr6nfWcg2gIAM+ozmtS1RmJKKC/YtWFpryMAY4t2epyOK3rNvNX52KkdKsEi1LavIIl3KhY9R2NJC7q772BP3Tj1HGau29qCykNv3DnnlSPWntaq0xHlhQOmf1qnFsa7DrYgsFDFeOa0Ydqr8zHcOlULfaWIUbsZHSrSt8uMgH6ZxTHyllj8m7BK5xn0pyyMARnK4+961WjldOVYHk5G006OTzA2eFH8IoKZbiw20giUnkjpipBhAT5qxv0Kn5qrRtCYwEDq/VmJ4x9KfmLySSYWI5DBPmNWmZO4ye4eRfmlHlj8P0qrM6bMBx70rtHKwPmQj1BjPFZ11Ijy/MwY5x8gwtRJjt0Qy5TAIXk/wBKoMMSoWJx3yKuzEKuRuzjIwe1QuCW5ZWUgYJHrWbQ+Yrk4kOV6HJINNuh8w3ZAYAjmppFjVlDKwB4ypxmq02PMAZnIHTNIDL1OMMBtGeOa5u+hJA54IzXU3RC4JUsOck8iuZvyGBDOV54xxQNGJtUFmXO3AGPfNWVdkICtlPpUc0oQBfKIY9MdqkdjtUBOnWptY0Wo58sn7zA544pmCMbfl281OHULtlA3EenWopeR8h3KvUe1PyYmUTuEkgIC/1qseSwI+lXptpRi/DnmqhQhTyCfTFQxoglIKhT1HrVZyFbHNWJSrLyOaqSgkc9qjroDWhSuwC2R0FY93kvkfiK1pmVmI4wO/vWdOoKZHXPIqou6E9DKvPuE469qxLnLOfpW5ckEHpisK/yCSucY5rqg77GEtjmNZ5dPxFR21woj2uxBHt1qXVvm2nuD0rMrvivdOCW53sSs5JyB25p2zH+sXIqvGZFyFJIqx9rwNsoOKxsFxkoh2EgAexFc3rpCFUDgluSB2ra1C9gjjJLjIHAPU1yVzKZ5mkbv2q6cXe4MjHBBrbOMZ5xWHW3GQUTHdRVVARo6fHkglgo64rXjgLn5QR6t7VnaagBUMPxrqLaFljBJVIj95h1rim9TpilY5rULPA/dgAjkE/xCqKnB2qNvOQPSuw1CyiMZIw8Z5z3rmdQhCyl7cMIx69quMr7g11RbtSZp4RHK5Y4DsT716j4eiECQ+ZIXbABGegryLTJBHLtZc91b0Nd94NvvMm8hpORj5SeDXPNJSNqbbVj2TRvnMezfj0BA/OuvslUj94QeMcDmuP0JN8cYYgLx0712Ng6gBVPzYxmqQzTtwqsDFHtJH50sk2Hbtnjmqss5Taw6DiojMZD8xwB3q+axSRdjbOTkk+1SI7Acbg3bniqccrKhLmpYZTndGFA9aVx3L6ySFFyTkE49aTzEhOcKGPXaOn0qJZf4nPzHqGp25TGpZFYg4JPWmK5MyhgXB4LZG/n8KWSZ4Ruiig3EYLbTmoJ5trbo4gof07UqyEx8tg44Pcml6A9tSCSRmAJjYjvzwKrSzQkhOjZzVx2KriQyMe/IxWdLlQUXPXrUu6FdETEF8dQc9KjZDnIVSD3x0pJJNnHHFVzcNGx3sNp/SpsP0JpJdqhCQwHQmop2ZVBcsT6H0qtLeW8StLdyxW8Q6PI4A/nXnPin4zaHpLPDpytqc/TERG0H3yKcYylsKUow3O4u5XJO0hV65JAAzXK3+pafcat/Zcdys2oFdxjj+YfUsOB+deQt4p8a/ETVE03TJWgSTh47Y7VVemXJ/GvXfDfhi08L6L/AGdYqhd0BvLneCbh/Xkn5emOlaSp8nxPUmFT2nwrTuVpGzcRx5QknPA7VfCAQ4z83qfSq1xZFZI3UBiOnzDj9au20ErnO0ZA5yw4/WsTVjGtgsYdgSR/ED0qjcM6S7XXCAYJHWtiSEt2Uf8AAx/jVWSN1b7q+3zD/GpGmzNbEuD90+g6VXnYHIbj0J71bm8xHyoG0Huw/wAapzKWPAUZ/wBof40DsUnPynYMN61VlJIHfFWpUIXBx+YqlMPLXAPXrUFvYpXGzrgDJxWXdSgfICMdq0JNygkgEdqx7zByVOSKqK7EMz5mCsUbp71j3cp+bjitC6k3Z47VgXZy2O1dUInNN9zK1IkqeeM5rNrQ1H6+1Z9d0Njie56FGqgZIyo7VTvp0SIlsbRU91cJHHlyqqOrZrldXvzcSFI2/dDjjvWUYO4rlK6naeZmPTPAqGiitwCtuzw0MZ9qxK2NLbNuB6E9azqbDjudLpcTZUjAPqeldRap03ZbPBx0Nc/pCB8BgxA9uOtdVaeamASqJ6GuCe52RGLbIrnzS3ltnO0VjX9gs42hsYHzADpXYx25Kh0UbTwQehqGS0CyMksSR9vMbg1mroq1zgorM23DAlSeWxzXReEkjg1iIuNolIH41eltHLKssaISd2V53VA6JbXlnKUC7XADg8Gm53dwirHtelYW3RRjAxz+FbUFzsI2nJxXK6RMJrePyzk4Hf2rbiYonzZLY9Kv0Kjpubq3GRjuRkZpgbPfr3rKFwQoLttYdAOtPE7ckc57DqaRRsAo23zHHTpQdythMp6ZrKguwzYkDLjoPWrjS74wYgDj86Gh6p2NGNwMb33cU4yhMP155z0rMtpEEn74lWP6VM5G3KOS3X2Io9BXs7GnNfIyABOR2HemxzHbtYhQR+VZRRmQ7FEYXnJP60xCWbas7t78YpNsNC3OzRvu3ZX0zUEt/vDDgDoQOtVruQoNjFmJ6snJFVGkC8b2PHcUikk9y0Jl35HJHArP1E3MttMtpMILsg+XIeimmmWNQC0qjByQD1p63THChAV7H1pITR88fEDw547eZpdVluNStyc/uCSv1xxXm44Yphgy8FSDkV9nPMqL80YOf4SAf51zPiLwT4e8SIxvLCOK4wAssShSvqeMV1wxNtJI5KmGvqmfPvgPS9e1i8u7XwxerbXOwF49+1pRnt9OtdU3gr4i97+U/wDbU1LrHwv13w3epqXhW++0vAdyDeElz6AA89MfjXoXhPxa2v2skGpQtY6/b8XFrNlWk/21BHf+lVOo/ijZomnTt7s7pnl8/hDx9G+x72UkHA/eGnr4Q+IHbUJP+/hr1uZ1Lq24nJ9etPGN/wAvAzzgnisvby7I29gu7PI/+EN+IQXP26XH/XQ1G/hLx+pAa/l5/wCmhr2oybk2R7yehzVW43c/NlQORnkGp9vLsh+wj1bPGn8JeOs7TeSHt/rDUL+FPGo63b/99mvYJ2AwqAhgOTnvWcWIYjcTk0nXl2QLDx7s8003w/4pttUgkvbl2hU5cbic12N2xL4XpV64O2fOCcdfSs+duGxgDOaxnNzepvSgoKyKs+EjZhk9q56/G0Hb1PNbM8vydQc+9Zt0FxhhgetKGjSHLuYN2Q0betYV1nJPpWxqTZcqnGD0rGvGzn+ddsNTkqPQyLssck1Uqzctv4FV661scjHPI7kl3ZifU0yn7T+VAQ+lMBlLTwp708R5GO9ADY1GTntWjpXDFc4HWqiw4Iq5YribHf1qJaoFudnoe6FgxZwpP93NdbaRoefMZSf9nI/H0rmtARpYiuzePUnGK6zTlZVVZsFCcc8Yrzp7nbHQv20ckeGScxI3XADA/XPSrKWp8wMZA7ddx+6B65qS0gG5lc47j0NaFvb7c+aN6kcgcY9sVKjoW2YEtlCLh4o2ZVzuDD5io9D6H2rB8QrtiAd1Zw33gfmI/wB2u6lsmSd9qBw3OM4z9TWDrdnjduiIbPAxn9ahxs9Ro6PwdMstlGrykAAA8cniuuFvdSv+5XcB91M1wPhxikSfIBIuCoXmu7h1W7kjVBiFQMbsc1qrWsEk73QSowVWkUrLz+GKdbzsT+8LH6jFU7q52oA5zg537utQCcKC2c5pj6Gy86dU6ei8mpImQkAqGB9WII/KsmG6Ug7WxnquP60LJG5I80oR6jAP40n5gn0OjDBkCEoijoCf600gozLKw2kbgynK49M1h+Y4PUk9Oe9Na6ZI13xrPEGyAJCMH8KVyde5qNIQQYrqCMr3aSj7W0ikyXdsyjuHwf0rFN80nL2iIwPykngf41PNM8sS5eN/VVjAA/GjcrbcsT3lsOWlVj/ssTVZrqHaGiZmGckNwB9PWqc8gzsBjjB9FBz/AIVnI6wyA7GyDnJ4x7gd6NtylZm2lxuPyrK0aDO4pwKC6E72lIHsKxJJo5T+4lkIzyWG0Z+lOiQSEsZBKo7E7Tn6Ug9TdEqsvymQqOp21GtwjE7QeOvvWWqsMGJ2C9wTUqTuflJwe2BQIumUszBXPX8QKzrqCJ5RJ5SeavRwoDfieppZZtjcjk+vFU55zyVPOcAD0o0DcjlfIKKQe3Xp9KkgkDEE7iB7VTeQlMMSCOpAqeIM0gYcr2HTNN6oZqmJCePvHoFOTUU52BvKZGPTr3pySBUIPMncjsKimIcK3cHnjAP40mBQlaR9xYhZAcYrNlkBd1lLJzzx1NXZ2VWYDhgc5J7Vk3MjyMQyhQO+c5qGWkQFoySWL+gI6VUuXBZgoYkY7cVJKzDhSABWbLIwkzuOfYVMYjZFM449fTsPxrPvmAUgZ6fnVmVtzMxHSsi8nIBUD5j3NXBXZDMu5bMjHI3Vj3jbRgjn1rYuQUBO7nGT71gXkm5WIB56V2U2clVmZNy+c0zgf/XpZPvUoxjpXWcpoSW2DxzR5Q2gHrWjJFgk561G0JBHFTclMo+UOTinCLH3fxq2Yccg09IjzwOlAXKapgZ61LGm2VST1qwI8kcdKUx4PA6Unsx63Oz8O3DW2wgcPxmuxt02plRu3HleuOa4zQWJgjwM/UV2elrzlXwff615817x2xehvWaO2AwGR0PerNviN8sWwOCcdfwqKyGcMDkHjPpVvPzEgMdpzgDg07DuTIglYhWbHcVV1WLdCvm5GR361pWsu5tpURuxzg96z9VO1yk7ZQdxzTtqMp6apt5FKYHvjNbnmsJEZuV74PWsa2KoytIuEPbdnirzSJ5Z2SEL1Ge1FtB31LdzuWJtygq3II5rDunCOMvtJHA64NXjMDHgPvYHg524rn9bkwGVFcyH/ZNRPRXLhvYsrNMkgzIGyeo4q0mpGGZkmCY/vda4J9QmtyQ5+uTiprbUElGbeZDnqr44/Oocuxcl3O/N+wUtbESEcglulUzqGpPOXSFQvfA4Ncl521VVphGSeqsMVpRatbW9vtjknafuA5YGk27auwttlc6qK8ecKSrtJ3XGAKZJer/y0hdAvXDEZrl1vrhv3sri3QcgFsE1BN4glmYJ8koX0IHFHN3EovodPNqliAUjifzO5ZjVV9TQghJGzjHK5Fcrc6nYSyHcrlu4VulSxSoVH2UDyj/fkBNNt9LF2Rvi7klbEjooHGBjn3q1bO2SY1wg6seKwCfu7/lkPAXbyK04fNMQBLPEOoI2UkwaRrPOJMBpMfSluHZIvlY49RyazmmiWMKn3j1GKjklKAZ3BTVN9yUrll7hhHg5256k81ELgknbgkDr0qCdyyqycKeMdc1Su5miDBiAH7DtU3s9RrVF1ZC7AckHnir9u5AOWHHasWJyjBcEAjjBzWjCilQVJcURYnubMDYUl8YPYdaW4I2qFfbu6DFU4ZAD3+XqKLiUqpI+YeuOlPoLqQXQU5xzjvWTdSghgOB+dTX1yrJnkAdcVh3bMz5U7Vx61LepaWmpBcSkMOcqOlV2kDhjjGOhqOWf5tg2596gmnAIVhhiOSOlNDuOmJBOMfMOorGvHC53YyBwauSzsgIUBh64rEuCzIwLd881rTVjGTKc8p8s7u9Yt1NnIWtC8lKhtwx2FY8zjBGOTXbTWhx1HqQMdxzTlOB0qOpUyBwa2ZkdTKmV649KYAcbT171OcEZfBFMOOuPxrPckZ5fHf8ACgoQmOBTlLF/7opWB/ipARbcYGfrTiMkbenNPwMZPHtTgp28KNo5ovpcfU6fw4dsSsHAIzjK5/CuytC8igqgDj7wH9K4jw5u8nAPUnAPSu1sNxjG+VY/Vscn8a457ux2R2N2CUocMMIeoAwc1eSQAFv3qL/EVYkY9OPeqFrJIgHmBLiIDtwxH1q1FOftKxtujixkqhx8vYE9+aQ0WDMVk2XKEv03ZxWVfXGZMBHypyWzkEUs88kOVuQHj7SNzzWZJdShXAIQZ+XcMgj0NFxl77XCzLwwwew3Y9+OtW0njEfzgsPboP8AgNc9FeyQHEuYT2MRxx7VPDdyqxdSJEPdR83/AAL1pc1ty+XQ2WB4Hy5ILKD3/HtVS9ldYyJAQpxypyyfiOoqNZkdCUcvH1MZ7H1FSRzWrbQsV3v7ZkHP0qeYaON1vTppCSsob03RkE/ia4u8gurSU/IAP9lga9ruDbtFiSwu5lbghp14rltW0OyJLxxzWan/AJ6HzD+G2lZJ9/68ylN9Tzy2umUhppCVH8Ldq2Ib3zYwtmTHKOSc9fpUk+igSHE0cqf3mhfOKzv7IdGLW8zAA9lKkfnR7r2Hdvcs3DStJi8uZJG7KMv/AC6U5Huidsds4j6bhEcn8cUyKD7NGHS7beeojVg5/GtTSb67kcRo98V6KDLjP44pNxRaUmRWtiZT+/hmjjIyWAKn65xWpZ2dkpP2SK5lk6AvJsH6jmt7T/tzrsktpXB7zyh1H4VprZySAGZtPJHABiLAfQZo5brT8iXNp6/mUbBJpBktE1y2AWdfu+nJ61pp58ahHj3sOpLcNSxWGFG0eavXd/Ao78dqe08UK+UyyMR0daadlqS3d6EDpM3JjiHPZQMVWeXLhcggdSxyB+FWJW+Xe8vyjkDBzWVcXUbDIiVTnBbb8uPYetKWwJXGXlyVm2xMGQDkgYye2PSs9pLg5EqoQBuIGMj61O43AsjLnHU+lQJH8/16gkZb6mpSuUUxqjRvshguJSOp2kD+XNbukaitwQqGRX7qVIx+NaGl6nLAoAit5olGMlcnH51YvL6KSIssEEJbliq80+Vb3Jc+jQu9hGWz8pPAHU++ar3EzgBsjIGCMjj3xVOS8VSNsiqRz8w3An04qjdX3CqhQsOSccn8aLoqKZJNOMncdpzyMVmy5X7zZGfl4zTZJS5Hzrg9d4yR9KilyCcmSM9AM8UctgbuVJPLZ2Yja56Dpmqdx+7zlh05HpWk8StgMpdvUnms+4UIdrRxn2xVQepNupTJmEeQq4HQFh+dZ19wnbkDJ681oyiLOHYAHqFU5H41l3hX7yHjtgYraKuZMxrsM8hUtkfSsy5GGx6VrXGSGJ6+o4rHmPze1dsDjkR1NGOOAD9ahFTrgKM9atknVMFJPPHpSHLcDgU8J700Dn39qy8hIVBhMUmMD1x60EbTjrmkfBUgcAdKE9dAGEqw3E/hT84QAdKRUwBjvTXHOCOaN0B0XhxmCnAB9V9q62wc71VoR5eep6rXIeHwGG3IHautsUcIytj29TXJNXkdcHodJCixlTGQ2OVqzOvmRMCXUH06oaztOncRhCpRh91vX2rU3pcQiN38pyuY3Hr6Gk3ctaGPfSAMzLvZZBlMnhfrXH32svBPJaTyuIvY8OPeun1mVZlZZZXhmTKtH2I9RXDarCgmxcMZM9JB/KpW+hW25Zg1ZN+xE+TORn+nvWtb6gcg2+0d8fxH61x4imiuBFE6qnVTWhbXDQkLOpJzkk/0qWralpo7ODUEmVRMFhZfugA9a0f9IkQHlge/cViadexSDaw3qRxu7V0diQY8byM/wnFTFNg7LoRJDdkhY4yynkluTU0llJCPN8+SCTsM8VpQIu07NgHQoOtTeRbgYIIB9e1Vyi5tTDCyyRFz9njGfml2ndUTW9jeEx3EyyyDo6qQRW7/AGdaHcftHlY/iWpUtY1AAmRlxk7gaWvUWhiWEWkWkpV7X7Ww77TgfnV+ePSJlXydNmicf3SAM1ba6K7lQovbABwagFzzh3Cj2FCdu33D5b6/qZ4to2Yqqsqj+96VPBBEP9QkIY/LuUfNVubdKpTzY9mOp61TaCCEYiOHB4am4jv0LRV0jcWzSxo3EgLD5vrVK5uJYeUIXAAIHWopyFQne3Pese4cpzG7sT1yRUuXYSVyxPdSvktKAR61mT3OT8zbj2JqjfXSc4Oxvc1iz6kFOGY/XNLUvRG5cXS4xtiIHUt0zWfJOnzKr7+eQO30rBub4SDaJTtzzg06K7I+SIBeOp701B9QTOpt7gRyAoZNwGc7hxVg3e5WKTkg9QTxXLLdFWwxLjrgGrEE0YAkZnRx/DS5egGy07RggNtJ/u8E1W+0HOFJZs/xGqRvDNgyq23+89SFnckoFwe57ChIdy1HuZxLK2cdM9zVxHEj72wOOtVreAyMu8McDI/xrSMCv91SPTPepbsL1KEgEhK8H6VUkiUk7FCkdTWtJGyDBVQBVC7VMEg/N15q46A9jLvjtK4XLY7VhXpIYLIVH0raujuU7VBOPxrInXeMAEkjqa6IWMZGLfbC2EPy1kTn5zW3eptJ3HisSf8A1hrsp7HHLcYKnRdy9+Peo4lz9Kmj4UA9ask6tyYyGIyPSmA5Gcce1SHJUg8ikCAYKHjvmsiUNdQRznFRttJAxgCpmIz0DUwKd3ygqfcUl2GNKlFXB6/nijOVPXPQUsiBjkk5PX0pAM5AHT1709tQNvw5Gob95n2xXap80aBPvdc1xuh7mwy8KprpIpSpw/y989/wrkqbs6YbHQad5mzzljBQ8HHXNb8cSTWwjuJCZAc4OPmHrXPaNKqyMZLmKPcMxsx4257+9dPp5EKb3YeVn7x+6f8AZJpI0uZN9Cj2jtiK4x8kiHpj+ded+IYYrPcsILW7c5bqteyXlkjsJII1jl6OO/1Udx9a4nxR4evJI5pLY70GSUKjd+VRK6fMVFp6M8tSVPMKlQy/3WrTgeaABkEc0J6pnJArH1CSRXaKVQjKSOO1JZzojrmWRWJxkdvcVaZVtdTrNN1KGE/JkljjYeldVaZwrpHJADyc9K5XRLq2SQJcSTCQ/wDPGNWMn0zXV2eniE+fbLJbgnpL1/KspX6FXRs2906Y8w+YOxPWtWC6Mx2xqMD1rNtDOcHzoWPqvJrVtnuNp3MzA9BtAFNElwMJAPMVXHcGnqiB/MhtZMHsg6U+Ff3WWtZi3+yvyn6mlCT7nktorZdvRWkYM30FUKxWcquR9xugDjk1WdyN25Hz34HNXZZrsEtMrLjn7oyfeqLXjSE4jVmH97g0OQ1EptLBFlmg/enoTWXd31tESZLhox3HpWpPLcHI+zhR6msW6F4zlkYIR0JUYrOcrf8ADFxj3Mu81e1cf6PdK49O/wDKuev9RlYlYg7Htitm/wBP1OTLi4+buFRcViXMV2hIluYgxGMtwaj4nd6F2SWhi3U8xPMBZj6k1k3HnRt858snnDVqX8LLziGVu53mswQzsCEUgHrnkV0QsZO5R80ZO1yOeasRMmAFkYevqKsR6bdzON4f0wqjn2FaVr4XkLBZFm8w/wAIUcD35pynHYIxfUpRsVwLZ3ZvUirkU0kZUtnce7DgVtW/h14f+WCZxyrnBrTg0NUw0lnGsijOYyWDfXNY8yZpY59JI5XUyHzm+nFXoLZ3cAW7qSMY9K3rbTCDl4oT/sJyT9avQ6UcbMKsuflOeFqbt7BojMsInQBBg/7vNaLIAnzEKB27mrUdmsKdmJ6mLnJ9/SlZSudrLHjqG71NmJmPOhbknAPQVQmixuz0962LlMncZNxrPuN0hP7wY9u1XFA2c/cJGuTxvPQCs25Q4Lc++a15gFkOGB+nOaybskbt2cdhXREykc9qb8gAYzWE4zNj1Nbt+SzE8Z9ugrGiXN2oPc1209EcU9zU0/TDPCSvWpzpbgnC/pXVaBppNuH2E++OK0G0o5yABmnfUyTuc5JGQTtBBpi5AA6Cu5vNAZFJcBdvqRzWJcaSSzNHGzfSoaBSTMAqFIHUmlGCCHGPStCXTJQfuYx6mq8tpKGBwB+NSirlMcuA3Q9/Sh1AB284qz9nIBJAJ+tQS5QjHSku4zX8PAnKtgKe2e9dLDvaJo3AY9nHWua0GT5skDrmumkbKLIhAJ9+9c8tJXOiOxa0lWjmBbYVHIYnOK7nSn3LvG2UY2kdse1cPp7FpVZypI6nPSuz0KZQ3l7dhBwT2zUrQ0budJbpvjVUXCDjnr9frST6ZHOjqXYoR9x/l/Wp7UK6rwVbp16H+talsoU4kQ5P8WKfkB4v428ERyb57UOH5yoUY6+teY3Gn3NlK0bx7hnkDFfXVzYLKmSAR3FcV4i8OQSZby1DcnIxx+lRZx+E0jPozxjQbeH5ILhfnPIDnGPoetd7pVpCpC+axcdBnOKzrzS3s5yLhVkRTxjA6+9bunQRMgKElcc4H6ZqE7y1Rb2Ny1glwBkSDuCoU/pVlUkVvlBC56MMAVXg2qmAGHvk1oQMRjcRj881poyFoSYRSpMhGORg8fh61IokkkZlnCgjqQAacSCOVTaOvNHlxvkhm2HsB+lAXKtwVjUme6fIOPujFUt5lII8t0HQt8ufyrVaxXf8/wAyHpkVWmt9rERQvt+nFGoroyJjEzEMVX2D5rPkAXCpKNpPGe1bbq6qdqR9ed2KzLqMtksgz7dqTRSepmzR7V2s6nJz8pzWPqDMMgKrH/dHNas9sV+YAhc9zVZUcycev8QrFspJbnNS2LzNvMYZj0BAGKu2Hhsy4knhEhHQ5xiuqtbYSNlsD6Ctq0tEb+9+Aqkm9wcjBsNAgiQAwgsTwRzzW3DpSxxkCIBupGBmtWK0A2hAcg9CasGLODk5HU1SSRL1MP8As2NF3Nl89sCq509A3znb6A10joq8jPSqjxDO5hnPqKLIFcxJLfYcFMr0GB0pGtgEGM7RzitKbCE4qo6/Jnk55o6j6FKYKqn5QB0GKoXKoU3NyvoauzkHKrwBxgmqMmwoQSSBSY0rGZMBkkqpH1rLupCQxCDAHatKZ+SMfSsbUHcx7V4JPakld2HIzWYBc7gCKx7x1LYAJJ5NaUrBWAIwwrIu87ieR26V0QjyoyluY17gEkjC+lZNmd1+mf71al6cKxbr6Vmaau++Ttlv612x2OGXU9Y8OkeREpwQMcg1ttgsdy5NZegxILJQeuATWnjaSCC1S/Iyid7LpEERwcyP6k1nz6YTkooUH0ru5bJANyjJ96qzWHy56e3WtWjJM82n0FXkw5ODVZvDcRY8Egds16NPYryCMAc5qubLLEAduTS5UPmOATw3DLHlY+e/Nc54q0VLO33ouB3r2BLNUUhQfr/Sud8Z6bv09iBnA54+tJx00Gpa3PJdEZIzlhkZ6V2FkkZXaRlW5FcnYIgmZGyoB9PpXXaYiFNrMc5riqLU7YPQdYw/vZEAwAc11GmMYVAPzY4571jrEVukGcMw5bHBFbdqrcL3xjd/Q/41NrI0i7s6zSWDYZQQMY5/nXQ2mRxnK9s1y2mviNV7dDzjH+NdFYynC7gFI9eRU31NLGpGWHytxmqd3b74yCgP061Zifcm45GO3rQ0ikYVsP0IIo9QaOH1jTI2eRtu4dCpPrXN2tqba6KxthOykV6NqUQIYFRn27++a5C5tis5ZMgg9GGc1LWzKi3sPjUc5JB9KuW4U9MnNJbmTbhoV+uQaljSLcCytk+jYoYyzCPm24zn9Kmlt5pYwuFQ9Mk4zSwmOEh+cdeBzV3dFIyCVjgD+72p6EXZk3Fm8ShN+7jOQ/SqUwMakLJN9MHmt1rWEIcM+SODzVOS3f8Ah3MR0pWXQpO5zc7uCQI5AfXBNZ8nmMQZC3Wuqmjzk4dSPXJqnJagtu4OOxGKGr7Mu9jCaNpI8K/0zUkdmQBwpY+pq89srHBYIeTkLmrdvAsWd6M4I6//AFqm1yWytDbkKoIGfQc1sWtuTnHAH60sKBArINvplc5q1sViN6MAeoVsZp3JEWNQQ3fpwelKxzGwRcAc81MQWBVEUDpnPaoWjPO7kjpzRcZXlBAJByfpVe4Pyn+96VPI20nccD25qlKy8sWP9aCitLkZB6+lVbmQqnyj5h706VwQSm4gd81SnIYDlsjnFFrDK0uVVicMxrLmmG5hzwPSrlyWXgday5c726kHrSk7IuKuU55s5I5rMunOzJH4VozrjOSB6AVm3mI05YZPpVQCRlzjKlyfnP6VlXrt90kdK1LgjHJ4rIucKxPUH1reD7mEzE1H51J6VT0Jd9/GD6irOpMNr0vheMPfLkdCOfxrsjscE+p6ppQzbqEHIxxWkZm44/GqenA/Z0IIGBjOKnYSA8qfwNIyPd5P9Wv0qKTrHRRWrMIlW6/1b/WoIPvD8KKKSL6jG6yfhWJ4n/48ZfpRRR0EeJ/8v0v1FdNpvUfSiivPq7nfT2N5v9RD9RW1D/rpfp/WiiiRpA07b/WD/dH866a3+6n0oorLqbdDUt+oqGb/AF8n1oopPYcd2V7v/lh9f61zOo/8fL/WiijoCJIf9WPpR3/GiiqYkX4fvxVbb77fSiioFInT/j1T6/40kHVvpRRTiUU7r7p+lZV992T/AHaKKQ4lRP4Poa0rP7o+ooopx2JkX4/9b+H9KfB/rG+hooquhJHH/rPxol+7P9aKKhFPczbj7x+lULnq30oopPc0RSi6N9ap3H3m+tFFW9gW7KM/VKzpej0UVlPZFwMq7+7WPqH3kooqlsBm333H+grJvPuj6miiumBzyMDVPuv9at+Ef+P1aKK7eiOCoer6T/x6j6j+VXH+8aKKldSEf//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The prepatella bursa (arrow) is palpated for warmth, focal tenderness, and swelling, and the walls are squeezed between the fingertips to assess for bursal wall thickening. After assessing the acute and chronic inflammatory changes, the range of motion of the knee is assessed. The patient with prepatellar bursitis is able to fully extend the knee without increasing their symptoms.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Bruce C Anderson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_3_19504=[""].join("\n");
var outline_f19_3_19504=null;
var title_f19_3_19505="Patient information: Ingrown toenail (The Basics)";
var content_f19_3_19505=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/17198\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_picture\" href=\"UTD.htm?21/12/21697\">",
"         Ingrown toenail",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Ingrown toenail (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/ingrown-toenail-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H3580270\">",
"      <span class=\"h1\">",
"       What is an ingrown toenail?",
"      </span>",
"      &nbsp;&mdash;&nbsp;An ingrown toenail happens when the side or corner of your toenail grows into the flesh around it (",
"      <a class=\"graphic graphic_picture graphicRef78487 \" href=\"UTD.htm?21/12/21697\">",
"       picture 1",
"      </a>",
"      ). It usually affects the big toe.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H3580285\">",
"      <span class=\"h1\">",
"       What are the symptoms of an ingrown toenail?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The symptoms include pain, redness, and swelling where the nail has grown into the flesh.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H3580300\">",
"      <span class=\"h1\">",
"       Is there a test for an ingrown toenail?",
"      </span>",
"      &nbsp;&mdash;&nbsp;No. Your doctor or nurse should be able to tell if you have it by learning about your symptoms and doing an exam. &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H3580315\">",
"      <span class=\"h1\">",
"       Is there anything I can do on my own to feel better?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Some people feel better if they:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Place a small piece of a cotton ball or some dental floss underneath the nail to take pressure off the toe.",
"       </li>",
"       <li>",
"        Soak the foot in warm, soapy water. Do this for 10 to 20 minutes, 2 to 3 times a day for 1 to 2 weeks. You can also use 1 to 2 teaspoons of Epsom salts (available in drug stores) in the water instead of soap.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H3580330\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;See your doctor or nurse if redness and swelling become worse and there is pus.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H3580344\">",
"      <span class=\"h1\">",
"       How is an ingrown toenail treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If the treatments you have tried on your own don&rsquo;t help, your doctor might cut away part of your toenail. He or she will first inject a medicine to numb your toe. Afterwards, you will need to: &nbsp;",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Clean the area 2 to 3 times per day. Make a mixture of equal parts of water and",
"        <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/41/41617?source=see_link\">",
"         hydrogen peroxide",
"        </a>",
"        and dab it on your toe with a cotton swab.",
"       </li>",
"       <li>",
"        Put antibiotic ointment on your toe. Examples include",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?1/56/1925?source=see_link\">",
"         bacitracin",
"        </a>",
"        (brand name: Baciguent&reg;) and",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?5/63/6132?source=see_link\">",
"         mupirocin",
"        </a>",
"        (brand name: Bactroban&reg;). These are available over-the-counter.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H3580359\">",
"      <span class=\"h1\">",
"       Can an ingrown toenail be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You can reduce your chances of getting an ingrown toenail by:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Wearing shoes that are not too tight around your toes",
"       </li>",
"       <li>",
"        Cutting your toenails straight across and not too short",
"       </li>",
"      </ul>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?19/3/19505?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 17198 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.243-298F256B3B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_3_19505=[""].join("\n");
var outline_f19_3_19505=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3580270\">",
"      What is an ingrown toenail?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3580285\">",
"      What are the symptoms of an ingrown toenail?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3580300\">",
"      Is there a test for an ingrown toenail?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3580315\">",
"      Is there anything I can do on my own to feel better?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3580330\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3580344\">",
"      How is an ingrown toenail treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3580359\">",
"      Can an ingrown toenail be prevented?",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/17198\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?21/12/21697\">",
"      Ingrown toenail",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_3_19506="Castor oil: Pediatric drug information";
var content_f19_3_19506=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"12\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Castor oil: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?21/3/21554?source=see_link\">",
"    see \"Castor oil: Drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1045834\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Laxative, Stimulant",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1045829\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?21/3/21554?source=see_link\">",
"      see \"Castor oil: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Castor oil:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants &lt;2 years: 1-5 mL or 15 mL/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose as a single dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 2-11 years: 5-15 mL as a single dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &ge;12 years and Adults: 15-60 mL as a single dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Emulsified castor oil:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants: 2.5-7.5 mL/dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &lt;2 years: 5-15 mL/dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     2-11 years: 7.5-30 mL/dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &ge;12 years and Adults: 30-60 mL/dose",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F146837\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oil, oral: 100% (60 mL, 120 mL, 180 mL, 480 mL, 3840 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F146824\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Oil",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1045837\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Do not administer at bedtime because of rapid onset of action; chill or administer with milk, juice, or carbonated beverage to improve palatability; administer on an empty stomach; castor oil emulsions should be shaken well before use",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1045831\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Protect from heat (emulsion should be protected from freezing)",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1045836\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Preparation for rectal or bowel examination or surgery; rarely used to relieve constipation; also applied to skin as emollient and protectant",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F146856\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Hypotension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Electrolyte disturbance",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal cramps, diarrhea, nausea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Pelvic congestion",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1045840\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to castor oil; nausea, vomiting, abdominal pain, fecal impaction, GI bleeding, appendicitis, CHF, menstruation, dehydration",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1045828\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Long-term use may result in laxative dependence",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298980\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F146831\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F14206268\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ingestion of castor oil may be associated with induction of labor. Use of castor oil as a laxative during pregnancy should be avoided (Cullen, 2007; Hall, 2011; Wald, 2003).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1045833\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I &amp; O, serum electrolytes, stool frequency",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1045827\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Acts primarily in the small intestine; hydrolyzed to ricinoleic acid which reduces net absorption of fluid and electrolytes and stimulates peristalsis",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1045839\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Onset of action: Oral: Within 2-6 hours",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13121 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-197.136.42.3-071942397F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_3_19506=[""].join("\n");
var outline_f19_3_19506=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045834\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045829\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146837\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146824\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045837\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045831\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045836\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146856\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045840\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045828\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298980\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146831\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14206268\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045833\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045827\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045839\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13121\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13121|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?21/3/21554?source=related_link\">",
"      Castor oil: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_3_19507="Glutamine: Drug information";
var content_f19_3_19507=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Glutamine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?42/32/43523?source=see_link\">",
"    see \"Glutamine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F176566\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Enterex&reg; Glutapak-10&reg; [OTC];",
"     </li>",
"     <li>",
"      NutreStore&trade;;",
"     </li>",
"     <li>",
"      Resource&reg; GlutaSolve&reg; [OTC];",
"     </li>",
"     <li>",
"      Sympt-X G.I. [OTC];",
"     </li>",
"     <li>",
"      Sympt-X [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F176578\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Amino Acid;",
"     </li>",
"     <li>",
"      Gastrointestinal Agent, Miscellaneous",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F176567\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Nutritional supplement (Enterex&reg; Glutapak-10&reg;, Resource&reg; GlutaSolve&reg;, Sympt-X, Sympt-X G.I.): Oral: Average dose: 10 g 3 times/day; dosing range: 5-30 g/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Short bowel syndrome (NutreStore&trade;): Oral: 30 g/day administered as 5 g 6 times/day (every 2-3 hours while awake) for up to 16 weeks; to be used in combination with growth hormone and nutritional support",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F3062830\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15896362\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15896363\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling; use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F176551\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Powder for oral solution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Enterex&reg; Glutapak-10&reg;: 10 g/packet (50s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     NutreStore&trade;: 5 g/packet",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Resource&reg; GlutaSolve&reg;: 15 g/packet (56s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Sympt-X, Sympt-X G.I.: 10 g/packet (60s)",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F176553\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Enterex&reg; Glutapak-10&reg;: Prior to use, mix with clear liquids or semisolid food. If administering via feeding tube, mix each 10 g packet with &ge;60 mL water. Use immediately after preparation. May also be added directly to enteral formula if used within 24 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Resource&reg; GlutaSolve&reg;: Mix each 15 g packet with 120-240 mL of water. May also be mixed in hot or cold beverages, applesauce, or pudding. If administering via feeding tube, mix with 60-120 mL water. Use immediately after preparation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     NutreStore&trade;: Mix each packet (5 g) with ~240 mL of water prior to administration. May be given with meals or snacks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Sympt-X, Sympt-X G.I.: Mix dose with 6-8 ounces of juice or another beverage, may also be mixed with applesauce or pudding. Administer with meals. If administering via feeding tube, mix with &ge;60 mL water; do not add directly to feeding bag. Use immediately after preparation.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F176552\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NutreStore&trade;: Treatment of short bowel syndrome (SBS) when used in combination with specialized nutritional support and growth hormone therapy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OTC products: Medical food used to promote GI tract healing and nutritional supplementation with GI disorders, HIV/AIDS, cancer, and other critical illnesses",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F176576\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Facial edema, peripheral edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness, fever, headache, pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Pruritus, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, flatulence, nausea, pancreatitis, tenesmus, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, back pain, hypoesthesia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Ear or hearing symptoms",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Rhinitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Flu-like syndrome, infection, sepsis",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F176543\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; NutreStore&trade;: Should be used with nutritional support based on individual patient requirements.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Medical foods are intended to be used under the direction of a healthcare provider.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F13913728\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F176556\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reproduction studies have not been conducted.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F176571\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F176557\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The amount of total protein and free amino acids found in breast milk varies during lactation. Effects of the suggested oral dose of glutamine are unknown.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F176558\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     NutreStore&trade;: To be used in combination with a specialized diet. May be taken with food or a snack.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323171\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Glutamine Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (100): $12.96",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (L-Glutamine Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (50): $7.49",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pack",
"     </b>",
"     (NutreStore Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 g (84): $322.56",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F176549\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     BUN; body weight, nutritional status",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F176542\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Glutamine regulates gastrointestinal cell growth, function, and regeneration. Considered a &ldquo;conditionally essential&rdquo; amino acid during metabolic stress and injury.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F176555\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     As reported in healthy adults; parameters may vary following oral administration in patients with short bowel syndrome.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: I.V.: V",
"     <sub>",
"      d",
"     </sub>",
"     : 200 mL/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Via splanchnic tissue, lymphocytes, kidney, and liver to glutamate and ammonia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: I.V.: 1 hour",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Martindale RG, McClave SA, Vanek VW, et al, &ldquo;Guidelines for the Provision and Assessment of Nutrition Support Therapy in the Adult Critically Ill Patient: Society of Critical Care Medicine and American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.),&rdquo;",
"      <i>",
"       JPEN J Parenter Enteral Nutr",
"      </i>",
"      , 2007, 33(3):277-316.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/3/19507/abstract-text/19398613/pubmed\" id=\"19398613\" target=\"_blank\">",
"        19398613",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8747 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-188.40.116.55-F65976BBC3-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_3_19507=[""].join("\n");
var outline_f19_3_19507=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176566\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176578\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176567\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3062830\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15896362\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15896363\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176551\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176553\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176552\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176576\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176543\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13913728\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176556\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176571\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176557\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176558\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323171\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176549\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176542\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176555\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8747\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8747|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?42/32/43523?source=related_link\">",
"      Glutamine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_3_19508="Polysaccharide-iron complex and folic acid: Drug information";
var content_f19_3_19508=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Polysaccharide-iron complex and folic acid: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?38/25/39316?source=see_link\">",
"    see \"Polysaccharide-iron complex and folic acid: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F13185999\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F13186000\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      NovaFerrum&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F13186004\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Iron Salt",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F13186024\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Iron deficiency (prevention/treatment):",
"     </b>",
"     Oral: 5 mL daily",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F13186023\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Children &gt;12 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F13186025\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F13204280\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder for solution, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     NovaFerrum&reg;: Elemental iron 100 mg and folic acid 1 mg per 5 mL (120 mL) [contains ascorbic acid 60 mg/5 mL; raspberry-grape flavor]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F13186002\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F13186007\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prevention and treatment of iron-deficiency anemias",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F13186015\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gastrointestinal: Abdominal pain, constipation, dark stools, diarrhea, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Miscellaneous: Hypersensitivity reaction",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F13186011\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to iron salts or any component of the formulation; hemosiderosis, hemochromatosis, or hemolytic anemias",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F13186012\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Anemia: Not appropriate for use with pernicious, aplastic, or normocytic anemias when anemia is present with vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     deficiency.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Pernicious anemia: Folate doses &gt;0.1 mg/day may obscure pernicious anemia in that hematologic remission can occur with continuing irreversible nerve damage progression.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Pediatrics:",
"     <b>",
"      [U.S. Boxed Warning]: Accidental overdose of iron-containing products is a leading cause of fatal poisoning in children under 6 years of age. Keep this product out of the reach of children. In case of accidental overdose call the poison control center immediately.",
"     </b>",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299907\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F13225905\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the absorption of Iron Salts.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: Iron Salts may decrease the serum concentration of Bisphosphonate Derivatives.  Management: Avoid administration of oral iron supplements within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Pamidronate; Zoledronic Acid.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cefdinir: Iron Salts may decrease the serum concentration of Cefdinir. Red-appearing, non-bloody stools may also develop due to the formation of an insoluble iron-cefdinir complex.  Management: Avoid concurrent cefdinir and oral iron when possible.  Separating doses by several hours may minimize interaction.  Iron-containing infant formulas do not appear to interact with cefdinir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferiprone: Iron Salts may decrease the serum concentration of Deferiprone.  Management: Separate administration of deferiprone and oral medications or supplements that contain polyvalent cations by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dimercaprol: May enhance the nephrotoxic effect of Iron Salts.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eltrombopag: Iron Salts may decrease the serum concentration of Eltrombopag.  Management: Separate administration of eltrombopag and any orally administered polyvalent cation (e.g., iron-containing products) by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: Folic Acid may decrease the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Green Tea: May decrease the serum concentration of Folic Acid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     H2-Antagonists: May decrease the absorption of Iron Salts.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Levodopa: Iron Salts may decrease the serum concentration of Levodopa. Only applies to oral iron preparations.  Management: Consider separating doses of the agents by 2 or more hours to minimize the effects of this interaction. Monitor for decreased therapeutic effects of levodopa during concomitant therapy, particularly if doses cannot be separated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Levothyroxine: Iron Salts may decrease the serum concentration of Levothyroxine.  Management: Separate oral administration of iron salts and levothyroxine by at least 4 hours.  Separation of doses is not required with parenterally administered iron salts or levothyroxine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methyldopa: Iron Salts may decrease the serum concentration of Methyldopa.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pancrelipase: May decrease the absorption of Iron Salts.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PenicillAMINE: Iron Salts may decrease the absorption of PenicillAMINE. Only oral iron salts are a concern.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PHENobarbital: Folic Acid may decrease the serum concentration of PHENobarbital.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: Folic Acid may decrease the serum concentration of Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphate Supplements: Iron Salts may decrease the absorption of Phosphate Supplements.  Management: Administer oral phosphate supplements at least 1 hour before, or 2 hours after, oral iron salt administration.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Potassium Phosphate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Primidone: Folic Acid may decrease the serum concentration of Primidone. Additionally, folic acid may decrease concentrations of active metabolites of primidone (e.g., phenobarbital).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Proton Pump Inhibitors: May decrease the absorption of Iron Salts.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: Iron Salts may decrease the absorption of Quinolone Antibiotics. Of concern only with oral administration of both agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Raltitrexed: Folic Acid may diminish the therapeutic effect of Raltitrexed.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetracycline Derivatives: Iron Salts may decrease the absorption of Tetracycline Derivatives. Only a concern with orally administered products.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trientine: Iron Salts may decrease the serum concentration of Trientine. Trientine may decrease the serum concentration of Iron Salts.  Management: Trientine manufacturer recommends avoiding concurrent administration with oral iron salts due to the risk for impaired GI absorption of both trientine and the iron salt. Short courses of iron may be used however separate administration by at least 2 hours",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13186008\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is recommended that pregnant women meet the dietary requirements of iron with diet and/or supplements in order to prevent adverse events associated with iron-deficiency anemia in pregnancy. Treatment of iron-deficiency anemia in pregnant women is the same as in nonpregnant women, and in most cases, oral iron preparations may be used. Except in severe cases of maternal anemia, the fetus achieves normal iron stores regardless of maternal concentrations.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F13186009\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F13186010\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Iron is normally found in breast milk. Breast milk or iron-fortified formulas generally provide enough iron to meet the recommended dietary requirements of infants. The amount of iron in breast milk is generally not influenced by maternal iron status.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Folic acid requirements are increased during pregnancy; a deficiency may result in fetal harm.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F13186026\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dietary sources of iron include beans, cereal (enriched), clams, beef, lentils, liver, oysters, shrimp, and turkey. Foods that enhance dietary absorption of iron include broccoli, grapefruit, orange juice, peppers and strawberries. Foods that decrease dietary absorption of iron include coffee, dairy products, soy products, spinach, and tea.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322913\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (NovaFerrum Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100-60-1 mg/5 mL (120 mL): $42.28",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American College of Obstetricians and Gynecologists, &ldquo;ACOG Practice Bulletin No. 95: Anemia in Pregnancy,&rdquo;",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2008, 112(1):201-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/3/19508/abstract-text/18591330/pubmed\" id=\"18591330\" target=\"_blank\">",
"        18591330",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Baker WF Jr, &ldquo;Iron Deficiency in Pregnancy, Obstetrics, and Gynecology,&rdquo;",
"      <i>",
"       Hematol Oncol Clin North Am",
"      </i>",
"      , 2000, 14(5):1061-77.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/3/19508/abstract-text/11005034/pubmed\" id=\"11005034\" target=\"_blank\">",
"        11005034",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      IOM (Institute of  Medicine),",
"      <i>",
"       Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc",
"      </i>",
"      , Washington, DC: National Academy Press, 2001.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Nutrition During Lactation.&rdquo; Subcommittee on Nutrition During Lactation, Committee on Nutritional Status During Pregnancy and Lactation, Food and Nutrition Board Institute of Medicine, National Academy of Sciences Washington, DC: National Academy Press, 1991. Available at",
"      <a href=\"file://www.nap.edu\" target=\"_blank\">",
"       file://www.nap.edu",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Recommendations to Prevent and Control Iron Deficiency in the United States. Centers for Disease Control and Prevention,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 1998, 47(RR-3):1-29.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/3/19508/abstract-text/9563847/pubmed\" id=\"9563847\" target=\"_blank\">",
"        9563847",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Routine Iron Supplementation During Pregnancy. Review Article. US Preventive Services Task Force,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1993, 270(23):2848-54.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/3/19508/abstract-text/8133626/pubmed\" id=\"8133626\" target=\"_blank\">",
"        8133626",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16800 Version 18.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-201.65.114.212-C0B5FDA9AB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_3_19508=[""].join("\n");
var outline_f19_3_19508=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13185999\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13186000\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13186004\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13186024\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13186023\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13186025\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13204280\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13186002\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13186007\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13186015\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13186011\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13186012\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299907\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13225905\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13186008\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13186009\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13186010\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13186026\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322913\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/16800\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/16800|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?38/25/39316?source=related_link\">",
"      Polysaccharide-iron complex and folic acid: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_3_19509="AIP phlebitis Light LP";
var content_f19_3_19509=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F74906&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F74906&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Autoimmune pancreatitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 270px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Low power view of a pancreas biopsy in a patient with autoimmune pancreatitis. Obliterative phlebitis is present focally (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Russell Dorer, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_3_19509=[""].join("\n");
var outline_f19_3_19509=null;
var title_f19_3_19510="Nondisplaced tibial shaft fracture";
var content_f19_3_19510=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F85950&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F85950&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Nondisplaced tibial shaft fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 433px; height: 602px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This&nbsp;nondisplaced, stable, distal tibial diaphyseal fracture (yellow arrow in images A and B) was treated nonoperatively. Weight bearing was started at 4 weeks and was full at 6 weeks. Union was uneventful (images C and D). A long leg cast was used for 4 weeks followed by a patellar-tendon bearing cast as shown here (image E).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Petrisor BA, Bhandari M, Schemitsch E. Tibia and fibula fractures. In: Rockwood and Green's Fractures in Adults, 7th ed, Bucholz RW, Heckman JD, Court-Brown CM, Tornetta P (Eds), Lippincott Williams &amp; Wilkins, Philadelphia, 2010. Copyright &copy; 2010 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_3_19510=[""].join("\n");
var outline_f19_3_19510=null;
var title_f19_3_19511="Aluminum hydroxide and magnesium hydroxide: Pediatric drug information";
var content_f19_3_19511=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Aluminum hydroxide and magnesium hydroxide: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?1/54/1895?source=see_link\">",
"    see \"Aluminum hydroxide and magnesium hydroxide: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?24/2/24612?source=see_link\">",
"    see \"Aluminum hydroxide and magnesium hydroxide: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F132519\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Alamag [OTC];",
"     </li>",
"     <li>",
"      Mag-Al Ultimate [OTC];",
"     </li>",
"     <li>",
"      Mag-Al [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F132520\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Diovol&reg;;",
"     </li>",
"     <li>",
"      Diovol&reg; Ex;",
"     </li>",
"     <li>",
"      Gelusil&reg; Extra Strength;",
"     </li>",
"     <li>",
"      Mylanta&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F997188\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antacid",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Gastrointestinal Agent, Gastric or Duodenal Ulcer Treatment",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F997198\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?1/54/1895?source=see_link\">",
"      see \"Aluminum hydroxide and magnesium hydroxide: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Chronic administration is not recommended in children (Rudolph, 2001); dosing information for children is limited; very few published clinical trials are available. The following pediatric dosing represents suggestions from review articles (for children &lt;12 years) or product labeling (children &ge;12 years):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Liquid (aluminum hydroxide 200 mg and magnesium hydroxide 200 mg per 5 mL):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children &lt;12 years: 0.5-1 mL/kg/dose after meals and at bedtime (maximum dose: 15 mL) (Orenstein, 1988)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children &ge;12 years and Adults: 10-20 mL 4 times/day (maximum daily dose: 80 mL/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Suspension (aluminum hydroxide 500 mg and magnesium hydroxide 500 mg per 5 mL): Children &ge;12 years and Adults: 10-20 mL 4 times/day, between meals and at bedtime (maximum daily dose: 45 mL/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet (aluminum hydroxide 300 mg and magnesium hydroxide 150 mg):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children 6-11 years: 1-2 tablets 4 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children &ge;12 years and Adults: 1-2 tablets after meals and at bedtime, or as needed (maximum: 16 tablets/day)",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F132513\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Liquid, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Mag-Al:  Aluminum hydroxide 200 mg and magnesium hydroxide 200 mg per 5 mL (30 mL) [dye free, ethanol free, sugar free; contains propylene glycol, sodium 4 mg/5 mL; peppermint flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Suspension, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mag-Al Ultimate: Aluminum hydroxide 500 mg and magnesium hydroxide 500 mg per 5 mL (20 mL) [contains propylene glycol, sodium 4 mg/5 mL; peppermint flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, chewable:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Alamag: Aluminum hydroxide 300 mg and magnesium hydroxide 150 mg [contains phenylalanine 2.63 mg; wild cherry flavor]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F132502\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F5977909\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Liquid, suspension: Shake suspensions well before use; administer 1-2 hours after meals when stomach acidity is highest",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet: Chew tablets thoroughly before swallowing or allow tablets to dissolve slowly in mouth; follow by a full glass of water",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F5977906\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at room temperature; avoid freezing",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F997189\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adjunct for the relief of heartburn, peptic ulcer pain, and to promote healing of peptic ulcers; relief of stomach upset associated with hyperacidity",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F132533\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Constipation, chalky taste,  cramping, fecal discoloration (white speckles), fecal impaction, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypophosphatemia (rare), hypermagnesemia (rare)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F5977903\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to aluminum hydroxide, magnesium hydroxide, or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F6092065\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with decreased bowel motility, dehydration, diarrhea, appendicitis, gastric outlet obstruction, and in patients who have an upper GI hemorrhage. There are reports of osteomalacia and osteoporosis due to aluminum toxicity associated with use. Prolonged antacid therapy may result in hypophosphatemia; aluminum in antacid may form insoluble complexes with phosphate leading to decreased phosphate absorption in the GI tract. Rarely, severe hypophosphatemia can lead to anorexia, muscle weakness, malaise, and osteomalacia. Use with caution in patients with renal impairment; avoid use in severe renal impairment; hypermagnesemia or aluminum intoxication may occur in severe renal impairment, particularly with prolonged use. Aluminum intoxication may lead to osteomalacia or dialysis encephalopathy. Some tablets  may contain phenylalanine which must be avoided (or used with caution) in patients with phenylketonuria",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F10897644\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Some liquids/suspensions contain propylene glycol; in neonates large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; use liquids/suspensions containing propylene glycol with caution in neonates.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298723\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F132508\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Antacids may decrease the serum concentration of ACE Inhibitors.  Management: Separate fosinopril administration from antacids by at least 2 hours. US and Canadian recommendations for use of other ACE- inhibitors with antacids may vary. Consult appropriate labeling. Monitor for decreased therapeutic effects of ACE-inhibitors.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Enalaprilat; Ramipril.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfacalcidol: May increase the serum concentration of Magnesium Salts.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Allopurinol: Antacids may decrease the absorption of Allopurinol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists: Antacids may decrease the excretion of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dipivefrin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: Antacids may decrease the excretion of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticonvulsants (Hydantoin): Antacids may decrease the serum concentration of Anticonvulsants (Hydantoin).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotic Agents (Phenothiazines): Antacids may decrease the absorption of Antipsychotic Agents (Phenothiazines).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ascorbic Acid: May increase the absorption of Aluminum Hydroxide.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atazanavir: Antacids may decrease the absorption of Atazanavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisacodyl: Antacids may diminish the therapeutic effect of Bisacodyl. Antacids may cause the delayed-release bisacodyl tablets to release drug prior to reaching the large intestine.  Gastric irritation and/or cramps may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: Antacids may decrease the serum concentration of Bisphosphonate Derivatives.  Management: Avoid administration of antacids containing polyvalent cations within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Pamidronate; Zoledronic Acid.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: Magnesium Salts may decrease the serum concentration of Bisphosphonate Derivatives.  Management: Avoid administration of oral magnesium salts within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Pamidronate; Zoledronic Acid.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: Antacids may decrease the serum concentration of Bosutinib.  Management: Administer antacids more than 2 hours before or after bosutinib.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcitriol: May increase the serum concentration of Magnesium Salts.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers: May enhance the adverse/toxic effect of Magnesium Salts. Magnesium Salts may enhance the hypotensive effect of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Polystyrene Sulfonate: Laxatives may enhance the adverse/toxic effect of Calcium Polystyrene Sulfonate. More specifically, concomitant use of calcium polystyrene sulfonate with magnesium-containing laxatives may result in metabolic alkalosis or with sorbitol may result in intestinal necrosis.  Management: Avoid concomitant use of calcium polystyrene sulfonate (rectal or oral) and magnesium-containing laxatives or sorbitol.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Polystyrene Sulfonate: Antacids may enhance the adverse/toxic effect of Calcium Polystyrene Sulfonate. The combined use of these two agents may result in metabolic alkalosis and/or loss of efficacy of the cation exchange resin.  Management: To minimize this interaction, consider: a)separating doses by 2 or more hours; b)rectal administration of the exchange resin; or c)alternatives to antacids. Monitor for metabolic alkalosis and attenuation of CPS effects. Avoid magnesium hydroxide.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Polystyrene Sulfonate: May enhance the adverse/toxic effect of Aluminum Hydroxide. More specifically, concomitant use of these agents  may increase the risk for intestinal obstruction. Management: Monitor for signs/symptoms of intestinal obstruction with concomitant use of calcium polystyrene sulfonate and aluminum hydroxide. Adequate fluid intake, laxative use, alternative antacid agents, and/or limiting duration of therapy may help reduce risks.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cefditoren: Antacids may decrease the serum concentration of Cefditoren.  Management: Concomitant use of cefditoren with antacids is not recommended. Consider alternative methods to control acid reflux (eg, diet modification) or alternative antimicrobial therapy. If antacid therapy can not be avoided, separate dosing by several hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cefpodoxime: Antacids may decrease the serum concentration of Cefpodoxime.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cefuroxime: Antacids may decrease the serum concentration of Cefuroxime.  Management:  Consider administering antacids and cefuroxime at least 2 hours apart.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chenodiol: Aluminum Hydroxide may decrease the serum concentration of Chenodiol.  Management: Consider administration of chenodiol 2 hours before or 6 hours after aluminum-containing antacid products to prevent adsorption in the gastrointestinal tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chloroquine: Antacids may decrease the serum concentration of Chloroquine.  Management: Separate administration of antacids and chloroquine by at least 4 hours to minimize any potential negative impact of antacids on chloroquine bioavailability.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Citric Acid Derivatives: May increase the absorption of Aluminum Hydroxide.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Oral): Antacids may decrease the bioavailability of Corticosteroids (Oral).  Management: Consider separating doses by 2 or more hours. Budesonide enteric coated tablets could dissolve prematurely if given with drugs that lower gastric acid, with unknown impact on budesonide therapeutic effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: Antacids may decrease the serum concentration of Dabigatran Etexilate.  Management: Dabigatran etexilate Canadian product labeling recommends avoiding concomitant use with antacids for 24 hours after surgery. In other situations, administer dabigatran etexilate 2 hours prior to antacids. Monitor clinical response to dabigatran therapy.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: Antacids may decrease the absorption of Dasatinib.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Aluminum Hydroxide may diminish the therapeutic effect of Deferasirox.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferiprone: Antacids may decrease the serum concentration of Deferiprone.  Management: Separate administration of deferiprone and oral medications or supplements that contain polyvalent cations by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferiprone: Magnesium Salts may decrease the serum concentration of Deferiprone.  Management: Separate administration of deferiprone and oral medications or supplements that contain polyvalent cations by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Delavirdine: Antacids may decrease the serum concentration of Delavirdine.  Management: Separate doses of delavirdine and antacids by at least 1 hour. Monitor for decreased delavirdine therapeutic effects with this combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dexmethylphenidate: Antacids may increase the absorption of Dexmethylphenidate. Specifically, antacids may interfere with the normal release of drug from the extended-release capsules (Focalin XR brand), which could result in both increased absorption (early) and decreased delayed absorption.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eltrombopag: Aluminum Hydroxide may decrease the serum concentration of Eltrombopag.  Management: Separate administration of eltrombopag and any polyvalent cation (e.g., aluminum-containing products) by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eltrombopag: Magnesium Salts may decrease the serum concentration of Eltrombopag.  Management: Separate administration of eltrombopag and any polyvalent cation (e.g., magnesium-containing products) by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elvitegravir: Antacids may decrease the serum concentration of Elvitegravir.  Management: Separate administration of antacids and the elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate combination product by at least 2 hours in order to minimize the risk for an interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Erlotinib: Antacids may decrease the serum concentration of Erlotinib.  Management: Separate the administration of erlotinib and any antacid by several hours in order to minimize the risk of a significant interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ethambutol: Aluminum Hydroxide may decrease the absorption of Ethambutol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fexofenadine: Antacids may decrease the serum concentration of Fexofenadine.  Management: No specific recommendations concerning the time required between their administration are provided. Separate administration of each agent by as much time as possible to decrease the risk of an interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gabapentin: Antacids may decrease the serum concentration of Gabapentin.  Management: Administer gabapentin at least 2 hours after antacid administration.  Monitor patients closely for evidence of reduced response to gabapentin therapy when both of these drugs are being used.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HMG-CoA Reductase Inhibitors: Antacids may decrease the serum concentration of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iron Salts: Antacids may decrease the absorption of Iron Salts.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ferric Gluconate; Ferumoxytol; Iron Dextran Complex; Iron Sucrose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Isoniazid: Antacids may decrease the absorption of Isoniazid.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Itraconazole: Antacids may decrease the serum concentration of Itraconazole.  Management: Administer itraconazole at least 1 hour after and 2 hours before administration of any antacids.  Itraconazole oral suspension may be less sensitive to the effects of decreased gastric acidity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketoconazole (Systemic): Antacids may decrease the serum concentration of Ketoconazole (Systemic).  Management: Administer oral ketoconazole at least 2 hours prior to use of any antacid product.  Monitor patients closely for signs of inadequate clinical response to ketoconazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Levothyroxine: Aluminum Hydroxide may decrease the serum concentration of Levothyroxine.  Management: Separate administration of oral levothyroxine and aluminum hydroxide by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mesalamine: Antacids may diminish the therapeutic effect of Mesalamine. Antacid-mediated increases in gastrointestinal pH may cause the premature release of mesalamine from specific sustained-release mesalamine products.  Management: Avoid concurrent administration of antacids with sustained-release mesalamine products.  Separating antacid and mesalamine administration, and/or using lower antacid doses may be adequate means of avoiding this interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methenamine: Antacids may diminish the therapeutic effect of Methenamine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: Antacids may increase the absorption of Methylphenidate. Specifically, antacids may interfere with the normal release of drug from the extended-release capsules (Ritalin LA brand), which could result in both increased absorption (early) and decreased delayed absorption.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Misoprostol: Antacids may enhance the adverse/toxic effect of Misoprostol. More specifically, concomitant use with magnesium-containing antacids may increase the risk of diarrhea.  Management: Avoid concomitant use of misoprostol and magnesium-containing antacids. In patients requiring antacid therapy, employ magnesium-free preparations. Monitor for increased adverse effects (e.g., diarrhea, dehydration).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May increase the serum concentration of Aluminum Hydroxide. Management: In patients with severe renal dysfunction, consider avoiding this combination of agents.  Administering agents at least 2 hours apart may help minimize the interaction(s).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): Antacids may decrease the serum concentration of Multivitamins/Minerals (with ADEK, Folate, Iron). Specifically, antacids may decrease the absorption of orally administered iron.  Management: Separate dosing of oral iron-containing multivitamin preparations and antacids by as much time as possible in order to minimize impact on therapeutic efficacy of the iron preparation.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mycophenolate: Antacids may decrease the absorption of Mycophenolate.  Management: Separate doses of mycophenolate and antacids by at least 2 hours. Monitor for reduced effects of mycophenolate if taken concomitant with antacids.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mycophenolate: Magnesium Salts may decrease the serum concentration of Mycophenolate.  Management: Separate doses of mycophenolate and oral magnesium salts. Monitor for reduced effects of mycophenolate if taken concomitant with oral magnesium salts.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents: Magnesium Salts may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nilotinib: Antacids may decrease the serum concentration of Nilotinib.  Management: Separate the administration of nilotinib and any antacid by several hours whenever possible in order to minimize the risk of a significant interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PenicillAMINE: Antacids may decrease the serum concentration of PenicillAMINE.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphate Supplements: Antacids may decrease the absorption of Phosphate Supplements.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Potassium Phosphate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphate Supplements: Magnesium Salts may decrease the serum concentration of Phosphate Supplements.  Management: Administer oral phosphate supplements at least 1 hour before, or 2 hours after, oral magnesium salt administration.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Potassium Phosphate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ponatinib: Antacids may decrease the serum concentration of Ponatinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: Antacids may decrease the absorption of Protease Inhibitors.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Darunavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: Antacids may decrease the excretion of QuiNIDine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNINE: Antacids may decrease the serum concentration of QuiNINE.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: Antacids may decrease the absorption of Quinolone Antibiotics. Of concern only with oral administration of quinolones.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: Magnesium Salts may decrease the absorption of Quinolone Antibiotics. Of concern only with oral administration of both agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rilpivirine: Antacids may decrease the serum concentration of Rilpivirine.  Management: Administer antacids at least 2 hours before or 4 hours after rilpivirine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Polystyrene Sulfonate: Laxatives may enhance the adverse/toxic effect of Sodium Polystyrene Sulfonate. More specifically, concomitant use of sodium polystyrene sulfonate with magnesium-containing laxatives may result in metabolic alkalosis or with sorbitol may result in intestinal necrosis.  Management: Avoid concomitant use of sodium polystyrene sulfonate (rectal or oral) and magnesium-containing laxatives or sorbitol.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Polystyrene Sulfonate: Antacids may enhance the adverse/toxic effect of Sodium Polystyrene Sulfonate. The combined use of these two agents may result in metabolic alkalosis and/or loss of efficacy of the exchange resin.  Management: To minimize this interaction, consider: a)separating doses by 2 or more hours; b)rectal administration of the exchange resin; or c)alternatives to antacids. Monitor for metabolic alkalosis and attenuation of SPS effects. Avoid magnesium hydroxide.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Polystyrene Sulfonate: May enhance the adverse/toxic effect of Aluminum Hydroxide. More specifically, concomitant use of these agents  may increase the risk for intestinal obstruction. Management: Monitor for signs/symptoms of intestinal obstruction with concomitant use of calcium polystyrene sulfonate and aluminum hydroxide. Adequate fluid intake, laxative use, alternative antacid agents, and/or limiting duration of therapy may help reduce risks.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Strontium Ranelate: Aluminum Hydroxide may decrease the serum concentration of Strontium Ranelate.  Management: Separate administration of strontium ranelate and aluminum hydroxide by at least 2 hours whenever possible in order to minimize this interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Strontium Ranelate: Magnesium Hydroxide may decrease the serum concentration of Strontium Ranelate.  Management: Separate administration of strontium ranelate and magnesium hydroxide by at least 2 hours whenever possible in order to minimize this interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetracycline Derivatives: Antacids may decrease the absorption of Tetracycline Derivatives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetracycline Derivatives: Magnesium Salts may decrease the absorption of Tetracycline Derivatives. Only applicable to oral preparations of each agent.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trientine: Antacids may decrease the absorption of Trientine.  Management: Separate trientine dosing from other oral drugs (eg, antacids) by at least 1 hour. Monitor for decreased therapeutic effects of trientine if an antacid is initiated/dose increased, or increased effects if an antacid is discontinued/dose decreased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trientine: Magnesium Salts may decrease the serum concentration of Trientine. Trientine may decrease the serum concentration of Magnesium Salts.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ursodiol: Aluminum Hydroxide may decrease the serum concentration of Ursodiol.  Management: Consider administration of ursodiol 2 hours before or 6 hours after aluminum-containing antacid products to prevent adsorption in the gastrointestinal tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vismodegib: Antacids may decrease the serum concentration of Vismodegib.  Management: Carefully consider the need for any medication that increases the pH of the upper GI tract (PPIs, H2RAs, antacids), as these could significantly reduce vismodegib systemic exposure. Vismodegib dose increases are unlikely to compensate for this effect.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin D Analogs: May increase the serum concentration of Aluminum Hydroxide. Specifically, the absorption of aluminum may be increased, leading to increased serum aluminum concentrations.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F5977905\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Aluminum hydroxide forms insoluble salts with dietary phosphorus decreasing phosphorus absorption.",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F14286993\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F5977910\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     GI complaints, stool frequency; serum phosphate concentrations in patients on hemodialysis receiving chronic aluminum-containing antacid therapy; serum electrolytes in patients with renal impairment receiving magnesium-containing antacids",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F5977907\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Neutralizes gastric acidity increasing gastric pH; inhibits proteolytic activity of pepsin when gastric pH is increased &gt;4; binds bile salts",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F5977908\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Duration: Dependent on gastric emptying time",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fasting state: 20-60 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1 hour after meals: May be up to 3 hours",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F997204\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?24/2/24612?source=see_link\">",
"      see \"Aluminum hydroxide and magnesium hydroxide: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not intended for chronic use in pediatric patients. Antacids may impair or increase absorption of many drugs; do not take oral medications within 1-2 hours of an antacid dose unless specifically instructed to do so. Inform physician if symptoms do not improve within 2 weeks or if they worsen, or if black, tarry stools or coffee ground emesis occurs.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"'Inactive' Ingredients in Pharmaceutical Products: Update (Subject Review),\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1997, 99(2):268-78.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/3/19511/abstract-text/9024461/pubmed\" id=\"9024461\" target=\"_blank\">",
"        9024461",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nord KS, \"Peptic Ulcer Disease in the Pediatric Population,\"",
"      <i>",
"       Pediatr Clin North Am",
"      </i>",
"      , 1988, 35(1):117-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/3/19511/abstract-text/3124068/pubmed\" id=\"3124068\" target=\"_blank\">",
"        3124068",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Orenstein SR and Orenstein DM, \"Gastroesophageal Reflux and Respiratory Disease in Children,\"",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1988, 112(6):847-58.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/3/19511/abstract-text/3286854/pubmed\" id=\"3286854\" target=\"_blank\">",
"        3286854",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rudolph CD, Mazur LJ, Liptak GS, et al, \"Guidelines for Evaluation and Treatment of Gastroesophageal Reflux in Infants and Children: Recommendations of the North American Society for Pediatric Gastroenterology and Nutrition,\"",
"      <i>",
"       J Pediatr Gastroenterol Nutr",
"      </i>",
"      , 2001, 32 (Suppl 2):S1-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/3/19511/abstract-text/11525610/pubmed\" id=\"11525610\" target=\"_blank\">",
"        11525610",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shaffer SE and Levine S, \"Gastroesophageal Reflux in Children,\"",
"      <i>",
"       Hosp Pharm",
"      </i>",
"      , 2003, 38(3):212-7.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shapiro GG and Christie DL, \"Gastroesophageal Reflux in Steroid-Dependent Asthmatic Youths,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1979, 63(2):207-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/3/19511/abstract-text/440809/pubmed\" id=\"440809\" target=\"_blank\">",
"        440809",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sutphen JL, Dillard VL, and Pipan ME, \"Antacid and Formula Effects on Gastric Acidity in Infants With Gastroesophageal Reflux,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1986, 78(1):55-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/3/19511/abstract-text/3725503/pubmed\" id=\"3725503\" target=\"_blank\">",
"        3725503",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13382 Version 41.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-259ED97FEC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_3_19511=[""].join("\n");
var outline_f19_3_19511=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132519\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132520\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F997188\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F997198\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132513\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132502\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5977909\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5977906\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F997189\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132533\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5977903\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6092065\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10897644\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298723\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132508\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5977905\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14286993\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5977910\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5977907\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5977908\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F997204\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13382\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13382|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?1/54/1895?source=related_link\">",
"      Aluminum hydroxide and magnesium hydroxide: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?24/2/24612?source=related_link\">",
"      Aluminum hydroxide and magnesium hydroxide: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_3_19512="Chronic HP Light";
var content_f19_3_19512=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F70392%7EPULM%2F56574&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F70392%7EPULM%2F56574&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Chronic hypersensitivity pneumonitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 287px; height: 185px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Light micrograph from a patient with chronic hypersensitivity pneumonitis shows a pattern reminiscent of usual interstitial pneumonia. Other areas of the biopsy reveal granulomatous inflammation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Talmadge E King, Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Chronic farmer's lung",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 309px; height: 205px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Low power light micrograph from a patient with chronic farmer's lung shows bronchiolitis associated with fibrosis. Cholesterol clefts (arrow) are seen in the fibrotic region.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Talmadge E King, Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_3_19512=[""].join("\n");
var outline_f19_3_19512=null;
var title_f19_3_19513="AGEP";
var content_f19_3_19513=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F56807%7EALLRG%2F68610&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F56807%7EALLRG%2F68610&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Acute generalized exanthematous pustulosis (AGEP)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 354px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Confluent nonfollicular pustules superimposed on&nbsp;edematous erythema in a 46-year-old woman&nbsp;with AGEP. A skin biopsy showed intracorneal pustules with numerous neutrophils and neutrophilc infiltration of the epidermis and upper dermis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Copyright &copy; Vincent C.B. Lin, MD, Dermatlas; file://www.dermatlas.org.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Acute generalized exanthemous pustulosis (AGEP) detail",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 425px; height: 319px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <p>",
"     Nonfollicular, pinhead-sized&nbsp;pustules on a background of edematous erythema are characteristic of AGEP.",
"    </p>",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. Werner Pichler",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_3_19513=[""].join("\n");
var outline_f19_3_19513=null;
var title_f19_3_19514="Treatment of uncomplicated gonococcal infections";
var content_f19_3_19514=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of uncomplicated gonococcal infections",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/3/19514/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/3/19514/contributors\">",
"     Heidi Swygard, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/3/19514/contributors\">",
"     Arlene C Se&ntilde;a, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/3/19514/contributors\">",
"     Myron S Cohen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/3/19514/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/3/19514/contributors\">",
"     Noreen A Hynes, MD, MPH, DTM&amp;H",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/3/19514/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/3/19514/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/3/19514/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 1, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H7888990\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gonococcal infections, including urethritis, cervicitis, epididymitis, and proctitis, are a significant cause of morbidity among sexually active men and women. The treatment of these sexually transmitted infections (STIs) has evolved over the years, mainly due to the emergence of antibiotic resistance.",
"   </p>",
"   <p>",
"    Urogenital, anogenital, pharyngeal, and ocular gonococcal infections that are not associated with bacteremic or ascending spread of the pathogen to other organs are considered uncomplicated. This topic will address the treatment of these gonococcal infections, with a focus on urogenital infections. In 2012, the United States Centers for Disease Control and Prevention updated their guidelines on the treatment of Neisseria gonorrhoeae [",
"    <a class=\"abstract\" href=\"UTD.htm?19/3/19514/abstract/1\">",
"     1",
"    </a>",
"    ]. The information in this topic is largely consistent with those guidelines, as well as the 2010 sexually transmitted disease (STD) treatment guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?19/3/19514/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical manifestations and diagnosis of gonorrhea are discussed elsewhere. The treatment of complicated infections, such as disseminated gonococcal infection and pelvic inflammatory disease, is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/20/38217?source=see_link\">",
"     \"Epidemiology, pathogenesis, and clinical manifestations of Neisseria gonorrhoeae infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/38/29286?source=see_link\">",
"     \"Cutaneous manifestations of gonorrhea\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/35/26166?source=see_link\">",
"     \"Diagnosis of gonococcal infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/56/3976?source=see_link\">",
"     \"Disseminated gonococcal infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/63/35832?source=see_link&amp;anchor=H6#H6\">",
"     \"Treatment of pelvic inflammatory disease\", section on 'Recommended regimens'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7888997\">",
"    <span class=\"h1\">",
"     GENERAL BACKGROUND",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1115797\">",
"    <span class=\"h2\">",
"     Therapeutic principles",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is desirable for a therapeutic gonococcal regimen to:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Be highly effective at all anatomic sites of infection",
"     </li>",
"     <li>",
"      Be well tolerated (particularly in patients with recurrent infections)",
"     </li>",
"     <li>",
"      Offer the feasibility of single-dose therapy at the point of care",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Therapeutic regimens should have efficacy rates of greater than 95 percent because treatment failure has significant public health implications related to ongoing transmission of infection [",
"    <a class=\"abstract\" href=\"UTD.htm?19/3/19514/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Single-dose therapy decreases the reliance on patient adherence, which can negatively affect eradication rates and increase the risk of drug resistance. Because of progressive development of drug resistance to various classes of antibiotics, at present, only one drug,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    , meets these strict treatment efficacy goals with single-dose therapy, few adverse effects, and relatively low rates of drug resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?19/3/19514/abstract/5\">",
"     5",
"    </a>",
"    ]. However, decreasing susceptibility to this agent over time threatens the ability to effectively treat N. gonorrhoeae and has prompted recommendations for use of a combination therapy to treat gonococcal infections. (See",
"    <a class=\"local\" href=\"#H7889004\">",
"     'Antibiotic resistance'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H1115841\">",
"     'Approach to treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1115804\">",
"    <span class=\"h2\">",
"     Chlamydia as a copathogen",
"    </span>",
"    &nbsp;&mdash;&nbsp;The selection of antibiotics for the treatment of gonorrhea must also include the possibility of copathogens, such as Chlamydia trachomatis, which is often asymptomatic in women [",
"    <a class=\"abstract\" href=\"UTD.htm?19/3/19514/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Some epidemiologic surveys have shown a coinfection rate up to 46 percent among men and women with gonorrhea [",
"    <a class=\"abstract\" href=\"UTD.htm?19/3/19514/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/46/42728?source=see_link\">",
"     \"Genital Chlamydia trachomatis infections in women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/44/34505?source=see_link\">",
"     \"Treatment of Chlamydia trachomatis infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/18/18728?source=see_link\">",
"     \"Genital Chlamydia trachomatis infections in men\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7889004\">",
"    <span class=\"h1\">",
"     ANTIBIOTIC RESISTANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The era of antibiotic resistance began in the 1940s with the emergence of sulfonamide resistance. Subsequently, gonococcal infections were treated with penicillins, but by 1989, &gt;5 percent of cases of gonorrhea were caused by strains that produced a plasmid-mediated beta-lactamase and &gt;17 percent were associated with chromosomally-mediated resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?19/3/19514/abstract/3\">",
"     3",
"    </a>",
"    ]. As a pattern, N. gonorrhoeae has developed increasing minimum inhibitory concentrations (ie, decreasing susceptibility) followed by frank resistance to the antimicrobial class most commonly used for therapy, thus progressively reducing available therapeutic options [",
"    <a class=\"abstract\" href=\"UTD.htm?19/3/19514/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most of the data on gonococcal drug resistance is inferred through in vitro susceptibility data and epidemiologic surveys, rather than through clinical trials demonstrating increased treatment failure rates. In the United States, trends in drug resistance have been monitored by the Centers for Disease Control and Prevention (CDC)-sponsored Gonococcal Isolate Sensitivity Project (GISP), which was created in 1986 [",
"    <a class=\"abstract\" href=\"UTD.htm?19/3/19514/abstract/3\">",
"     3",
"    </a>",
"    ]. Similar programs have been collecting data on N. gonorrhoeae antimicrobial resistance in other regions of the world [",
"    <a class=\"abstract\" href=\"UTD.htm?19/3/19514/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Such surveillance programs have demonstrated increased resistance worldwide to multiple classes of antibiotics, including penicillins, tetracyclines, macrolides, and fluoroquinolones, with documented cross-resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?19/3/19514/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. An especially alarming trend in N. gonorrhoeae drug resistance has been the progressive decrease in susceptibility to the cephalosporins. &nbsp;",
"   </p>",
"   <p>",
"    The emerging threat of antimicrobial-resistant gonorrhea appears to be more evident among men who have sex with men (MSM) than among men who have sex exclusively with women (MSW). Recent surveillance data from GISP which included more than 34,000 episodes of symptomatic gonorrhea found that isolates from MSM were significantly more likely to demonstrate antimicrobial resistance to all the antibiotic classes noted above, including cephalosporins, than isolates from MSW [",
"    <a class=\"abstract\" href=\"UTD.htm?19/3/19514/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H77502526\">",
"    <span class=\"h2\">",
"     Cephalosporins",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rising rates of gonococcal resistance to non-cephalosporin classes of antimicrobial agents led to the use of cephalosporins, particularly intramuscular injections of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    and oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/44/16070?source=see_link\">",
"     cefixime",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?19/3/19514/abstract/14\">",
"     14",
"    </a>",
"    ]. However, trends in increasing mean minimum inhibitory concentrations (MICs) of N. gonorrhoeae for both agents, indicating decreasing susceptibility, have been reported worldwide and have led to changes in the recommendations for use of these agents. (See",
"    <a class=\"local\" href=\"#H278540\">",
"     'Preferred regimen for urogenital infection'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H365932\">",
"    <span class=\"h3\">",
"     Cefixime",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surveillance of N. gonorrhoeae samples in the United States between 2006 and 2011 demonstrate decreasing susceptibility to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/44/16070?source=see_link\">",
"     cefixime",
"    </a>",
"    among reported isolates [",
"    <a class=\"abstract\" href=\"UTD.htm?19/3/19514/abstract/15\">",
"     15",
"    </a>",
"    ]. Although the Clinical and Laboratory Standards Institute (CLSI) has not defined criteria for gonococcal resistance to cefixime, it considers gonococcal isolates with an MIC &ge;0.25",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    for this agent to have an &ldquo;elevated MIC.&rdquo; The percentage of isolates with such elevated cefixime MICs increased 15-fold from 2006 to 2011 [",
"    <a class=\"abstract\" href=\"UTD.htm?19/3/19514/abstract/1\">",
"     1",
"    </a>",
"    ]. Although no confirmed treatment failures with cefixime have been reported in the United States as of 2012, such failures have been reported in Europe and Japan [",
"    <a class=\"abstract\" href=\"UTD.htm?19/3/19514/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]. Furthermore, in a retrospective study of patients treated for culture-confirmed N. gonorrhoeae infection with a single oral dose of cefixime 400 mg at a Canadian clinic, 13 of 133 patients who returned for a test of cure were again culture positive, and nine (6.8 percent) were considered treatment failures [",
"    <a class=\"abstract\" href=\"UTD.htm?19/3/19514/abstract/19\">",
"     19",
"    </a>",
"    ]. With regards to location of infection, clinical failure occurred in 4 of 76 urethral, 2 of 7 pharyngeal, and 3 of 39 rectal infections (5.3, 28.6, and 7.7 percent, respectively). Although the possibility that some of these cases represented reinfection instead of treatment failure cannot be definitively excluded, these data highlight the increasing concern of the inadequacy of cefixime for gonococcal infections.",
"   </p>",
"   <p>",
"    In light of current domestic MIC trends and international treatment failures, we agree with the CDC recommendation that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/44/16070?source=see_link\">",
"     cefixime",
"    </a>",
"    should not be a preferred agent for the treatment of gonorrhea. (See",
"    <a class=\"local\" href=\"#H195635372\">",
"     'Other cephalosporins'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H365939\">",
"    <span class=\"h3\">",
"     Ceftriaxone",
"    </span>",
"    &nbsp;&mdash;&nbsp;There has also been a progressive creep over time towards higher MICs for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    globally, as reflected by resistance patterns in isolates reported to surveillance programs in the United States, Canada, Latin America, Europe, Australia, and Asia [",
"    <a class=\"abstract\" href=\"UTD.htm?19/3/19514/abstract/9,10,15,18,20-23\">",
"     9,10,15,18,20-23",
"    </a>",
"    ]. As an example, between 2000 and 2010, the proportion of gonococcal isolates with decreased susceptibility to ceftriaxone (MIC &ge;0.125",
"    <span class=\"nowrap\">",
"     mcg/mL)",
"    </span>",
"    reported from men in the United States increased from 0.1 to 0.3 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?19/3/19514/abstract/15\">",
"     15",
"    </a>",
"    ]. In Bangladesh, 1.5 percent of the isolates reported in 2000 through a World Health Organization surveillance program demonstrated reduced susceptibility to ceftriaxone [",
"    <a class=\"abstract\" href=\"UTD.htm?19/3/19514/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In 2011, the first N. gonorrhoeae strain with high-level resistance to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    (MIC 2 to 4",
"    <span class=\"nowrap\">",
"     mcg/mL)",
"    </span>",
"    was isolated from the pharynx of a sex worker in Japan [",
"    <a class=\"abstract\" href=\"UTD.htm?19/3/19514/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. This was followed by a report from France of a different ceftriaxone-resistant strain isolated from the urethra of a man who had sex with men (MSM) and had earlier failed treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/44/16070?source=see_link\">",
"     cefixime",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?19/3/19514/abstract/26\">",
"     26",
"    </a>",
"    ]. Additionally, ceftriaxone treatment failure has been documented in a heterosexual man in Sweden who had a pharyngeal infection with a N. gonorrhoeae strain with a pretreatment MIC of 0.125",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?19/3/19514/abstract/27\">",
"     27",
"    </a>",
"    ]. His pharyngeal cultures remained positive despite sequential doses of 250 and 500 mg and only cleared following a 1 gram dose.",
"   </p>",
"   <p>",
"    These developments highlight the pressing need for improving control of the spread of drug resistance in N. gonorrhoeae and clinically investigating other viable therapeutic options [",
"    <a class=\"abstract\" href=\"UTD.htm?19/3/19514/abstract/8,28,29\">",
"     8,28,29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H77502541\">",
"    <span class=\"h2\">",
"     Azithromycin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drug resistance to macrolides has also been reported. In the United States, data from the GISP demonstrate increasing MICs for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    since surveillance for the drug&rsquo;s activity against N. gonorrhoeae began in 1992. In 2004, almost 1 percent of gonococcal isolates had an azithromycin MIC &gt;1",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?19/3/19514/abstract/30\">",
"     30",
"    </a>",
"    ]. In 2011, a cluster of five cases of N. gonorrhoeae with reduced sensitivity to azithromycin (MIC range 8 to 16",
"    <span class=\"nowrap\">",
"     mcg/mL)",
"    </span>",
"    was reported in San Diego County, representing 9 percent of all isolates collected within a three-month span; and in 2012, the first isolate in the United States with high-level resistance to azithromycin (MIC &gt;512",
"    <span class=\"nowrap\">",
"     mcg/mL)",
"    </span>",
"    was identified in Hawaii [",
"    <a class=\"abstract\" href=\"UTD.htm?19/3/19514/abstract/31,32\">",
"     31,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In Europe, the prevalence of decreased susceptibility to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    (MIC &ge;1",
"    <span class=\"nowrap\">",
"     mcg/mL)",
"    </span>",
"    ranges from none (eg, in France and the United Kingdom) to 30 percent in Slovakia, with a mean of 7 percent across 21 countries [",
"    <a class=\"abstract\" href=\"UTD.htm?19/3/19514/abstract/9\">",
"     9",
"    </a>",
"    ]. Azithromycin resistance is also not uncommon in China [",
"    <a class=\"abstract\" href=\"UTD.htm?19/3/19514/abstract/33\">",
"     33",
"    </a>",
"    ]. One laboratory study of gonococcal isolates in Hong Kong from 2005 to 2010 demonstrated that 30 percent of all gonococcal isolates were azithromycin-resistant [",
"    <a class=\"abstract\" href=\"UTD.htm?19/3/19514/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These findings emphasize the importance of ongoing drug resistance surveillance for all drugs commonly used in the treatment of gonorrhea [",
"    <a class=\"abstract\" href=\"UTD.htm?19/3/19514/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H366617\">",
"    <span class=\"h2\">",
"     Tetracycline",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     Tetracycline",
"    </a>",
"    resistance has been reported in the range of 10 to 20 percent of gonococcal isolates in the United States and Europe [",
"    <a class=\"abstract\" href=\"UTD.htm?19/3/19514/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. Cross-resistance to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    is presumed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H366145\">",
"    <span class=\"h2\">",
"     Aminoglycosides",
"    </span>",
"    &nbsp;&mdash;&nbsp;Resistance to spectinomycin has remained rare or undetected in systematic surveillance reports from the United States, Europe, and Australia [",
"    <a class=\"abstract\" href=\"UTD.htm?19/3/19514/abstract/9,10,35\">",
"     9,10,35",
"    </a>",
"    ]. However, this agent is not widely used in these areas. When it was used more frequently as a single agent, resistance was more common, as illustrated by a study of spectinomycin treatment for urethral gonorrhea in 99 United States military personnel in Korea, among whom spectinomycin monotherapy was the preferred regimen [",
"    <a class=\"abstract\" href=\"UTD.htm?19/3/19514/abstract/37\">",
"     37",
"    </a>",
"    ]. Eight of them (8.2 percent) experienced treatment failure, and six had infection with confirmed high-level spectinomycin resistance.",
"   </p>",
"   <p>",
"    Although susceptibility breakpoints for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    have not been defined for N. gonorrhoeae, the overall MICs are low across Europe [",
"    <a class=\"abstract\" href=\"UTD.htm?19/3/19514/abstract/9\">",
"     9",
"    </a>",
"    ]. They are not specifically reported in other parts of the world.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H77502534\">",
"    <span class=\"h2\">",
"     Fluoroquinolones",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of quinolone-resistant N. gonorrhoeae (QRNG) ranges from 10 to nearly 100 percent of isolates reported throughout the world, and these drugs are no longer recommended for the treatment of gonorrhea [",
"    <a class=\"abstract\" href=\"UTD.htm?19/3/19514/abstract/3,9,10,35\">",
"     3,9,10,35",
"    </a>",
"    ]. In several regions, such as the United States and Europe, the prevalence of quinolone resistance has decreased somewhat compared with previous years, likely reflecting decreased use of the drug [",
"    <a class=\"abstract\" href=\"UTD.htm?19/3/19514/abstract/9,35\">",
"     9,35",
"    </a>",
"    ]. However, resistance levels remain high elsewhere despite the avoidance of these drugs for treatment of gonorrhea and the resultant decrease in selection pressure. A potential explanation for this finding was suggested by a study that reported superior growth of a N. gonorrhoeae strain with a particular quinolone resistance mutation when compared with a nonmutated strain in both in vitro assays and an animal model [",
"    <a class=\"abstract\" href=\"UTD.htm?19/3/19514/abstract/38,39\">",
"     38,39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1115841\">",
"    <span class=\"h1\">",
"     APPROACH TO TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;As above, alarmingly increasing rates of antibiotic resistance to N. gonorrhoeae are reported worldwide. This has rendered the treatment of uncomplicated gonococcal infections more complex, with fewer treatment options than in the past [",
"    <a class=\"abstract\" href=\"UTD.htm?19/3/19514/abstract/11,40,41\">",
"     11,40,41",
"    </a>",
"    ]. Due to rising rates of gonococcal resistance to other agents (sulfonamides, penicillins, tetracyclines, and fluoroquinolones), third generation cephalosporins had been considered first-line monotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/3/19514/abstract/2\">",
"     2",
"    </a>",
"    ]. Of these,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    is favored because drug resistance has been documented less frequently than for other cephalosporins, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/44/16070?source=see_link\">",
"     cefixime",
"    </a>",
"    . However, as more isolates with decreased susceptibility to both cefixime and ceftriaxone are being reported, the ability to effectively treat N. gonorrhoeae is being threatened.",
"   </p>",
"   <p>",
"    As a result, several strategies to better manage gonorrhea in the setting of increasing cephalosporin resistance have been variably recommended by organizations such as the United States Centers for Disease Control and Prevention (CDC) and the British Association for Sexual Health and HIV (BASHH) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/3/19514/abstract/2,42\">",
"     2,42",
"    </a>",
"    ]. These include increasing the dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    administered as well as using an additional agent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H278540\">",
"    <span class=\"h2\">",
"     Preferred regimen for urogenital infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;For uncomplicated urogenital gonococcal infections, we suggest using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    plus a second agent at the following doses [",
"    <a class=\"abstract\" href=\"UTD.htm?19/3/19514/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"       Ceftriaxone",
"      </a>",
"      250 mg intramuscular in a single dose for treatment of gonococcal infection",
"      <br/>",
"      <br/>",
"      PLUS",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"       Azithromycin",
"      </a>",
"      (1 gram in a single oral dose) for possible additional activity against N. gonorrhoeae and for treatment of potential chlamydia coinfection",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     Doxycycline",
"    </a>",
"    (100 mg orally twice daily for seven days) is an alternate option for a second agent to administer with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    . Because of the increased prevalence of N. gonorrhoeae resistance to doxycycline compared with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    , we reserve the use of doxycycline for azithromycin-intolerant patients and for cases of epididymitis or proctitis, in which azithromycin has not been studied. (See",
"    <a class=\"local\" href=\"#H7889074\">",
"     'Epididymitis'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H7889081\">",
"     'Proctitis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In order to ensure adherence, we favor directly observed treatment whenever possible.",
"   </p>",
"   <p>",
"    Evaluation for cephalosporin resistance in patients with persistent or recurrent symptoms is essential to controlling the spread of drug resistance. Thus, all patients need to understand the importance of further evaluation if symptoms persist. (See",
"    <a class=\"local\" href=\"#H2836827\">",
"     'Monitoring for treatment failure'",
"    </a>",
"    below.) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H832751\">",
"    <span class=\"h3\">",
"     Efficacy of ceftriaxone",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     Ceftriaxone",
"    </a>",
"    has historically had high efficacy in the treatment of N. gonorrhoeae. However, in light of emerging antibiotic resistance data and because treatment failure has significant public health implications related to ongoing transmission of infection, ceftriaxone as a single agent for gonococcal infections is no longer recommended. Instead, ceftriaxone should be administered in combination with another agent. (See",
"    <a class=\"local\" href=\"#H1115932\">",
"     'Rationale for dual therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Earlier studies had suggested that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    dosed intramuscularly at either 125 mg or 250 mg resulted in microbiologic cure in 99 percent of uncomplicated urogenital and anorectal infections [",
"    <a class=\"abstract\" href=\"UTD.htm?19/3/19514/abstract/5\">",
"     5",
"    </a>",
"    ]. In a meta-analysis of trials comparing cephalosporins and other agents for treatment of uncomplicated gonorrhea, higher cure rates were reported with ceftriaxone 250 mg than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/44/16070?source=see_link\">",
"     cefixime",
"    </a>",
"    400 mg (OR 1.77, 95% CI 1.11-2.8) with equivalent side effects [",
"    <a class=\"abstract\" href=\"UTD.htm?19/3/19514/abstract/43\">",
"     43",
"    </a>",
"    ]. There was also a trend towards higher cure rates with ceftriaxone compared with spectinomycin. Thus, extensive data and clinical experience indicate that ceftriaxone is safe and effective for the treatment of uncomplicated gonorrhea at urogenital and anorectal sites and support its use as the preferred agent despite the need for parenteral administration. However, these studies predate the emergence of decreasing susceptibility to the cephalosporins. (See",
"    <a class=\"local\" href=\"#H7889004\">",
"     'Antibiotic resistance'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1116052\">",
"    <span class=\"h3\">",
"     Changes in dosing of ceftriaxone",
"    </span>",
"    &nbsp;&mdash;&nbsp;We agree with the 2011 CDC recommendation to dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    at 250 mg, which is an increase from the previously recommended dose of 125 mg [",
"    <a class=\"abstract\" href=\"UTD.htm?19/3/19514/abstract/2\">",
"     2",
"    </a>",
"    ]. This recommendation was based on scattered reports of cephalosporin treatment failures and the increasing identification of isolates with decreased susceptibility to cephalosporins (eg, increased minimal inhibitory concentration [MICs]) (see",
"    <a class=\"local\" href=\"#H77502526\">",
"     'Cephalosporins'",
"    </a>",
"    above). In addition, pharyngeal infection, which is often asymptomatic and may accompany infection at other sites, is more difficult to eradicate than gonococcal infections at other sites and may serve as a reservoir of infection [",
"    <a class=\"abstract\" href=\"UTD.htm?19/3/19514/abstract/44\">",
"     44",
"    </a>",
"    ]. However, a 98 percent cure rate has been documented among patients with pharyngeal gonorrhea who received a 250 mg dose of ceftriaxone, thus supporting the use of this dose [",
"    <a class=\"abstract\" href=\"UTD.htm?19/3/19514/abstract/45\">",
"     45",
"    </a>",
"    ]. Of note, a direct dosing comparison with 125 mg of ceftriaxone was not performed in this trial.",
"   </p>",
"   <p>",
"    Even higher doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    (500 mg) have been recommended by the BASHH in the United Kingdom [",
"    <a class=\"abstract\" href=\"UTD.htm?19/3/19514/abstract/42\">",
"     42",
"    </a>",
"    ]. A pharmacodynamic analysis suggested that such higher doses of ceftriaxone would result in less failure in the setting of elevated MICs [",
"    <a class=\"abstract\" href=\"UTD.htm?19/3/19514/abstract/20\">",
"     20",
"    </a>",
"    ]. However, there are no clinical data on the use of these doses for urogenital or anorectal gonococcal disease compared with 250 mg.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1115932\">",
"    <span class=\"h3\">",
"     Rationale for dual therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    cures approximately 98 to 99 percent of uncomplicated urogenital and anorectal infections [",
"    <a class=\"abstract\" href=\"UTD.htm?19/3/19514/abstract/2,4,5\">",
"     2,4,5",
"    </a>",
"    ]. However, because of trends in antimicrobial resistance and the lack of new, effective antimicrobials in advanced product development for use in the treatment of gonorrhea, we agree with the CDC recommendation for combination therapy for suspected or documented gonorrhea with ceftriaxone plus either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    , regardless of chlamydial coinfection status [",
"    <a class=\"abstract\" href=\"UTD.htm?19/3/19514/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. We favor azithromycin as a second agent, as above. Use of azithromycin with ceftriaxone is also recommended by government agencies in the United Kingdom [",
"    <a class=\"abstract\" href=\"UTD.htm?19/3/19514/abstract/42\">",
"     42",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H278540\">",
"     'Preferred regimen for urogenital infection'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The rationale for recommending dual therapy is mainly related to concerns regarding the early emergence of cephalosporin resistance and the paucity of alternative first-line agents. Although there are no clinical data to suggest that dual therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    decreases the emergence of resistance, some experts have suggested that a theoretical basis for dual therapy against N. gonorrhoeae could be extrapolated from evidence from other pathogens that demonstrates lower rates of resistance with the use of agents that act upon different molecular targets [",
"    <a class=\"abstract\" href=\"UTD.htm?19/3/19514/abstract/1\">",
"     1",
"    </a>",
"    ]. However, there are no data to support this hypothesis, and clinical trials are urgently needed to determine the most appropriate treatment strategy for N. gonorrhoeae in the face of rising antimicrobial resistance. &nbsp;",
"   </p>",
"   <p>",
"    Of note, there are real concerns regarding the efficacy of the second agent used (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    ) against gonococcal isolates in the event that resistance renders the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    ineffective. The prevalence of resistance to doxycycline is substantial and to azithromycin is increasing, and such trends may considerably limit the utility of these agents. (See",
"    <a class=\"local\" href=\"#H77502541\">",
"     'Azithromycin'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H366617\">",
"     'Tetracycline'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7889039\">",
"    <span class=\"h2\">",
"     Alternate therapies",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H195635372\">",
"    <span class=\"h3\">",
"     Other cephalosporins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other possible single-dose alternatives in the cephalosporin family include ceftizoxime 500 mg intramuscularly;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/57/35735?source=see_link\">",
"     cefotaxime",
"    </a>",
"    500 mg intramuscularly; or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/53/11094?source=see_link\">",
"     cefoxitin",
"    </a>",
"    2 g intramuscularly, administered with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/18/37157?source=see_link\">",
"     probenecid",
"    </a>",
"    1 g orally. These single-dose regimens are only recommended for uncomplicated urogenital and anorectal gonorrhea and should be combined with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    . They do not provide any advantage over parenteral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    plus azithromycin or doxycycline.",
"   </p>",
"   <p>",
"    If an injectable cephalosporin is not an option, oral cephalosporin therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    can be considered as second-line therapy.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/44/16070?source=see_link\">",
"     Cefixime",
"    </a>",
"    (400 mg orally in a single dose or 400 mg by suspension) was shown to lead to microbiologic cure in 96 percent of patients with uncomplicated gonorrhea [",
"    <a class=\"abstract\" href=\"UTD.htm?19/3/19514/abstract/45\">",
"     45",
"    </a>",
"    ]. Some limited data suggest that a single oral dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/44/27333?source=see_link\">",
"     cefpodoxime",
"    </a>",
"    (400 mg) may also be a possible alternative [",
"    <a class=\"abstract\" href=\"UTD.htm?19/3/19514/abstract/46\">",
"     46",
"    </a>",
"    ]. However, clinicians should be aware that gonococcal strains with decreased susceptibility to oral cephalosporins have been reported in the United States and throughout other parts of the world [",
"    <a class=\"abstract\" href=\"UTD.htm?19/3/19514/abstract/1,34,35,47\">",
"     1,34,35,47",
"    </a>",
"    ]. Thus, if oral cephalosporins are used in a combination regimen with azithromycin or doxycycline, patients should be advised to return in one week for a microbiological test of cure. (See",
"    <a class=\"local\" href=\"#H77502526\">",
"     'Cephalosporins'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H22560034\">",
"     'Test of cure'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H195635379\">",
"    <span class=\"h3\">",
"     Azithromycin monotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;While a 2 g single oral dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    monotherapy could treat both gonorrhea and chlamydia infections, it is not a recommended regimen due to the frequency of gastrointestinal side effects and concerns regarding increasing gonococcal drug resistance to azithromycin [",
"    <a class=\"abstract\" href=\"UTD.htm?19/3/19514/abstract/48\">",
"     48",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H77502541\">",
"     'Azithromycin'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    A lower dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    is not adequately effective against gonococcal infections. In a systematic review of studies in which azithromycin was used for treatment of uncomplicated urogenital infection, the aggregate cure rate for the 1 g dose fell just below the 95 percent cure rate, the efficacy threshold for gonorrhea [",
"    <a class=\"abstract\" href=\"UTD.htm?19/3/19514/abstract/49\">",
"     49",
"    </a>",
"    ]. In contrast, in a large randomized controlled trial, the 2 g dose had a cure rate of 99 percent (95% CI 97.9-100 percent), equivalent to that reported with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?19/3/19514/abstract/50\">",
"     50",
"    </a>",
"    ]. However, this higher dose was associated with gastrointestinal side effects in 35 percent.",
"   </p>",
"   <p>",
"    Thus, the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    as a single agent should be limited to patients with severe penicillin allergy who cannot undergo beta lactam desensitization protocols [",
"    <a class=\"abstract\" href=\"UTD.htm?19/3/19514/abstract/2,11\">",
"     2,11",
"    </a>",
"    ]. The evaluation and management of a patient with beta lactam allergy is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/46/23274?source=see_link\">",
"     \"Allergy to penicillins\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H195635386\">",
"    <span class=\"h3\">",
"     Spectinomycin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spectinomycin (2 g intramuscularly) is a safe and effective parenteral alternative that is only available outside of the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?19/3/19514/abstract/51\">",
"     51",
"    </a>",
"    ]. Spectinomycin serves as an alternate therapy for patients with a history of severe penicillin allergy. However, spectinomycin should not be used for treatment of pharyngeal infection as it is associated with low cure rates at this site [",
"    <a class=\"abstract\" href=\"UTD.htm?19/3/19514/abstract/5\">",
"     5",
"    </a>",
"    ]. Updated information from the CDC on the availability of spectinomycin will be available at",
"    <a class=\"external\" href=\"file://www.cdc.gov/std/Gonorrhea/default.htm\">",
"     www.cdc.gov/std/Gonorrhea/default.htm",
"    </a>",
"    , but as of 2012, there was no plan for spectinomycin distribution in the US.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1117033\">",
"    <span class=\"h2\">",
"     Other gonococcal infections",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7889046\">",
"    <span class=\"h3\">",
"     Pharyngeal infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the clinical data are more limited than for urogenital gonococcal disease, pharyngeal infections appear to be more difficult to cure and may serve as an important reservoir of infection [",
"    <a class=\"abstract\" href=\"UTD.htm?19/3/19514/abstract/2,44,52\">",
"     2,44,52",
"    </a>",
"    ]. This issue was well illustrated in a meta-analysis of 144 controlled and uncontrolled trials, which found that standard antimicrobial therapy led to cure rates of 79 percent for pharyngeal infections in men compared with 98 and 95 percent for urethral and rectal infections, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?19/3/19514/abstract/44\">",
"     44",
"    </a>",
"    ]. Three theories were proposed to explain the lower cure rate for pharyngeal infections:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Pharyngeal isolates are \"naturally\" less susceptible to antimicrobials",
"     </li>",
"     <li>",
"      Antimicrobials work less effectively at the mucosal surface of the pharynx",
"     </li>",
"     <li>",
"      Immune defense mechanisms are less effective at the mucosal surface of the pharynx than at other sites, and are therefore more dependent upon the efficacy of antimicrobial activity",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Treatment of pharyngeal infection follows the same principles outlined for the approach to therapy of uncomplicated urogenital gonococcal infections, above. Of note, alternate agents like spectinomycin,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/44/16070?source=see_link\">",
"     cefixime",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/44/27333?source=see_link\">",
"     cefpodoxime",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/61/26583?source=see_link\">",
"     cefuroxime",
"    </a>",
"    axetil are associated with low rates of gonococcal eradication in the pharynx and should not be used [",
"    <a class=\"abstract\" href=\"UTD.htm?19/3/19514/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H278540\">",
"     'Preferred regimen for urogenital infection'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7889060\">",
"    <span class=\"h3\">",
"     Conjunctivitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;One small study (n = 12 adults) of the treatment of gonorrhoeae conjunctivitis found a single 1 g intramuscular injection of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    to be effective [",
"    <a class=\"abstract\" href=\"UTD.htm?19/3/19514/abstract/53\">",
"     53",
"    </a>",
"    ]. All patients should also be treated presumptively for chlamydia infection as well with either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?19/3/19514/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/17/20760?source=see_link&amp;anchor=H5#H5\">",
"     \"Conjunctivitis\", section on 'Hyperacute bacterial conjunctivitis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7889074\">",
"    <span class=\"h3\">",
"     Epididymitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of epididymitis is generally empiric and thus depends upon clinical suspicion of the etiology.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Epididymitis is most likely to be caused by N. gonorrhoeae or C. trachomatis in men younger than age 35.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"       Ceftriaxone",
"      </a>",
"      (250 mg intramuscularly) and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      (100 mg orally twice for 10 days) is indicated in these patients. There are no data on the use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"       azithromycin",
"      </a>",
"      for chlamydia in patients with epididymitis. Azithromycin may be considered an alternative agent in patients with a history of",
"      <span class=\"nowrap\">",
"       intolerance/allergy",
"      </span>",
"      to doxycycline, but follow-up to evaluate for symptom resolution should be conducted.",
"     </li>",
"     <li>",
"      In men over the age of 35 years or in men who engage in anal insertive intercourse, epididymitis is frequently caused by enteric organisms.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/60/35776?source=see_link\">",
"       Ofloxacin",
"      </a>",
"      (300 mg orally twice daily for 10 days) or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"       levofloxacin",
"      </a>",
"      (500 mg orally once daily for 10 days) is the recommended treatment, unless N. gonorrhoeae infection is suspected.",
"     </li>",
"     <li>",
"      In addition to antibiotic treatment, analgesics, scrotal elevation, limitation of activity and use of cold packs can be helpful [",
"      <a class=\"abstract\" href=\"UTD.htm?19/3/19514/abstract/54\">",
"       54",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/20/44360?source=see_link&amp;anchor=H12#H12\">",
"       \"Evaluation of the acute scrotum in adults\", section on 'Epididymitis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7889081\">",
"    <span class=\"h3\">",
"     Proctitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with acute proctitis should be evaluated by anoscopy or sigmoidoscopy. If polymorphonuclear leukocytes are detected on a Gram-stained smear of anorectal secretions of a patient who has engaged in anoreceptive intercourse, the cause is usually sexually transmitted. Empiric therapy for both gonorrhea and chlamydia with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    (250 mg intramuscularly in a single dose) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    (100 mg orally twice a day for seven days) is indicated for the treatment of patients with acute proctitis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/3/19514/abstract/2\">",
"     2",
"    </a>",
"    ]. There are no data on the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    in patients with proctitis. Azithromycin may be considered an alternative agent in patients with a history of",
"    <span class=\"nowrap\">",
"     intolerance/allergy",
"    </span>",
"    to doxycycline, but patient follow-up to evaluate for symptom resolution is advised.",
"   </p>",
"   <p>",
"    There are multiple other etiologies for proctitis to be considered as well, including other sexually transmitted infections such as herpes simplex virus. Nonsexually transmitted causes of proctitis include Shigella spp, Campylobacter spp, and Entamoeba histolytica in immunocompetent patients and cytomegalovirus or other opportunistic pathogens in immunosuppressed HIV-positive patients. (See appropriate topic reviews).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1117152\">",
"    <span class=\"h3\">",
"     Pelvic inflammatory disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;N. gonorrhoeae is rarely documented as the causal pathogen in pelvic inflammatory disease (PID), but empiric treatment for this pathogen is an important component of PID management. Broad-spectrum antibiotic therapy, including coverage for C. trachomatis and anaerobes, is also warranted. The use of fluoroquinolones is not recommended due to drug-resistant N. gonorrhoeae [",
"    <a class=\"abstract\" href=\"UTD.htm?19/3/19514/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/63/35832?source=see_link\">",
"     \"Treatment of pelvic inflammatory disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14405271\">",
"    <span class=\"h3\">",
"     Disseminated gonococcal infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of septic arthritis due to N. gonorrhoeae and other manifestations of disseminated gonococcal infection is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/56/3976?source=see_link&amp;anchor=H20#H20\">",
"     \"Disseminated gonococcal infection\", section on 'Evaluation and management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H279604\">",
"    <span class=\"h2\">",
"     Specific populations",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H279612\">",
"    <span class=\"h3\">",
"     Penicillin allergic patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of the penicillin allergic patient depends on the clinical suspicion of true allergy and the type of the allergy (eg, morbilliform rash versus IgE-mediated reactions, such as urticaria). We agree with the CDC recommendation of treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    if the patient has only a history of rash without IgE manifestations [",
"    <a class=\"abstract\" href=\"UTD.htm?19/3/19514/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although a reaction to penicillin is the most commonly reported medication allergy by history, the vast majority of individuals are found not to be allergic when further testing is performed. Penicillin skin testing is the preferred method of evaluation of possible type I, IgE-mediated penicillin allergy. If penicillin skin testing is performed and is negative, patients may safely receive cephalosporins. Among penicillin skin test-positive patients, approximately 2 percent will react to a cephalosporin. Without precautions, some of these reactions could be severe or life threatening. Thus, options for management are to administer an unrelated antibiotic or to administer a cephalosporin using either a graded challenge or a rapid desensitization procedure (",
"    <a class=\"graphic graphic_algorithm graphicRef61102 \" href=\"UTD.htm?25/10/25760\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Alternate treatment choices among patients with a history of IgE-mediated drug reactions include spectinomycin (where available) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    (2 g as a single oral dose). However, emerging concerns regarding drug resistance should limit the use of azithromycin to these limited circumstances. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/19/15672?source=see_link\">",
"     \"Penicillin-allergic patients: Use of cephalosporins, carbapenems, and monobactams\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/62/29672?source=see_link\">",
"     \"Rapid drug desensitization for immediate hypersensitivity reactions\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/46/23274?source=see_link\">",
"     \"Allergy to penicillins\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If spectinomycin is used for pharyngeal gonorrhea, patients should have a culture of the oropharynx performed three to five days after treatment to verify eradication of infection, since eradication rates in this site are typically lower than other sites. (See",
"    <a class=\"local\" href=\"#H7889046\">",
"     'Pharyngeal infection'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H279639\">",
"    <span class=\"h3\">",
"     Pregnant women",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnant women with uncomplicated gonorrheal infection should be treated with dual therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    ;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    should be avoided during pregnancy. If the patient is allergic to cephalosporins, desensitization procedures should be employed prior to administration. Since the discontinuation of production of spectinomycin in January 2006 in the United States, the only other acceptable treatment alternative is azithromycin monotherapy (2 g orally) for both gonorrhea and chlamydia. A test of cure is recommended. (See",
"    <a class=\"local\" href=\"#H22560034\">",
"     'Test of cure'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    All pregnant women with pelvic inflammatory disease should be hospitalized and given parenteral antibiotics, due to the potential complications of infection resulting in adverse pregnancy outcomes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/63/35832?source=see_link\">",
"     \"Treatment of pelvic inflammatory disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4144011\">",
"    <span class=\"h1\">",
"     PATIENT COUNSELING",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4144073\">",
"    <span class=\"h2\">",
"     Sexual activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients should be counseled to avoid sexual activity until seven days following treatment initiation. They may subsequently resume having sex as long as their symptoms have resolved and their sex partners have been treated. (See",
"    <a class=\"local\" href=\"#H4144433\">",
"     'Management of sexual partners'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4144118\">",
"    <span class=\"h2\">",
"     HIV counseling and testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Persons diagnosed with a sexually transmitted infection are at high risk for HIV infection and should be routinely tested. One study demonstrated that 27 percent of persons who had recently acquired HIV infection (n = 191) were diagnosed with gonorrhea in the 12 months preceding HIV acquisition [",
"    <a class=\"abstract\" href=\"UTD.htm?19/3/19514/abstract/55\">",
"     55",
"    </a>",
"    ]. Details of HIV testing are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/12/35018?source=see_link\">",
"     \"Prevention of sexually transmitted infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20345?source=see_link\">",
"     \"Diagnostic assays for HIV infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/34/10793?source=see_link\">",
"     \"Serologic screening for HIV infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4144362\">",
"    <span class=\"h2\">",
"     Pregnancy testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with reproductive potential and urogenital gonococcal infection should undergo pregnancy testing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22560004\">",
"    <span class=\"h1\">",
"     PATIENT FOLLOW-UP",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22560034\">",
"    <span class=\"h2\">",
"     Test of cure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who finish a recommended regimen for treatment of uncomplicated gonorrheal infections (specifically, a combination regimen containing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    ) and have no further symptoms do not need to return for a test of cure [",
"    <a class=\"abstract\" href=\"UTD.htm?19/3/19514/abstract/2\">",
"     2",
"    </a>",
"    ]. However, we perform a test of cure seven days following therapy for any patient who receives an alternate regimen (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    monotherapy or a regimen based on an oral cephalosporin such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/44/16070?source=see_link\">",
"     cefixime",
"    </a>",
"    ), regardless of the initial anatomic site of infection. This test of cure can be culture-based or a nucleic acid amplification test (NAAT) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/3/19514/abstract/1,56\">",
"     1,56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We favor culture for test of cure as it also allows for susceptibility testing, and it is unknown if NAAT performed less than three weeks following therapy will result in false positive results due to detection of nonviable organisms after treatment (rather than persistent infection). If NAAT is used, attempts should be made to follow-up any positive test of cure with a confirmatory culture. &nbsp;In the absence of risk for reinfection, patients with a positive test of cure should be considered as suspected treatment failures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2836827\">",
"    <span class=\"h2\">",
"     Monitoring for treatment failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients should be instructed to return to care if they experience persistent or recurrent symptoms soon after completing therapy for gonorrhea. Men who have sex with men (MSM) appear to have a higher prevalence of antimicrobial-resistant gonococcal infections than men who have sex exclusively with women (MSW) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/3/19514/abstract/13\">",
"     13",
"    </a>",
"    ]. In addition to testing for other sexually transmitted infections (see",
"    <a class=\"local\" href=\"#H7889102\">",
"     'Postgonococcal urethritis'",
"    </a>",
"    below), the relevant specimens should be submitted for culture for N. gonorrhoeae and isolates sent for susceptibility testing [",
"    <a class=\"abstract\" href=\"UTD.htm?19/3/19514/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/35/26166?source=see_link&amp;anchor=H11473920#H11473920\">",
"     \"Diagnosis of gonococcal infections\", section on 'Culture'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Any case of suspected treatment failure (isolation of N. gonorrhoeae following therapy and low suspicion for repeat infection) or resistant gonococcal isolates should be reported to governmental public health agencies. In the United States, such cases can be reported to the Centers for Disease Control and Prevention (CDC) at 404-639-8659 and through state and local public health authorities.",
"   </p>",
"   <p>",
"    Retreatment with a higher dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    (eg, 500 mg), in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    , is a reasonable approach for patients who experience treatment failure following the recommended dose of ceftriaxone at 250 mg intramuscularly.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22560061\">",
"    <span class=\"h2\">",
"     Retesting",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients diagnosed with gonorrhea are at risk for repeat infection as well as infections with other sexually transmitted infections, including HIV. They should return at three months after treatment for retesting for N. gonorrhoeae. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/35/26166?source=see_link\">",
"     \"Diagnosis of gonococcal infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7889102\">",
"    <span class=\"h1\">",
"     POSTGONOCOCCAL URETHRITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postgonococcal urethritis refers to symptoms that persist after successful eradication of gonococcal infection. Postgonococcal urethritis may be related to other copathogens, such as chlamydia, trichomonas, or Mycoplasma genitalia. Herpes simplex virus (HSV) may also be a causative agent, although HSV is often distinguished from these other pathogens on physical examination.",
"   </p>",
"   <p>",
"    One study in Japan evaluated the incidence of postgonococcal urethritis in 390 men with culture-proven N. gonorrhoeae who were initially treated with either a cephalosporin or spectinomycin [",
"    <a class=\"abstract\" href=\"UTD.htm?19/3/19514/abstract/57\">",
"     57",
"    </a>",
"    ]. At enrollment, C. trachomatis, genital Mycoplasmas,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    genital Ureaplasmas were detected by polymerase chain reaction testing in 132 (34 percent) of the study participants. Three hundred twenty-seven patients (84 percent) returned to clinic after treatment for gonorrhea; 36 patients who had evidence of persistent gonococcal infection were excluded from further analysis. The study was significant for the following results:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One hundred four patients (36 percent) had persistent urethritis, as diagnosed by the presence of &ge;5 polymorphonuclear leukocytes; 41 of these patients were asymptomatic.",
"     </li>",
"     <li>",
"      In a multivariate analysis, C. trachomatis coinfection was associated with an 11-fold greater risk of postgonococcal urethritis.",
"     </li>",
"     <li>",
"      When 66 patients with chlamydial infection were excluded, coinfection with M. genitalium or U. urealyticum biovar 2 was independently associated with an increased risk of postgonococcal urethritis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This study supports concurrent treatment of chlamydia infection in patients with a diagnosis of gonorrhea [",
"    <a class=\"abstract\" href=\"UTD.htm?19/3/19514/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/44/34505?source=see_link\">",
"     \"Treatment of Chlamydia trachomatis infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Data also suggest that M. genitalium may be another frequent copathogen associated with gonococcal infection. A prevalence study conducted in 381 women attending a sexually transmitted infection (STI) clinic in North Carolina identified 23 patients with gonorrhea using nucleic acid amplification tests (NAATs); 30 percent of this subset was coinfected with M. genitalium [",
"    <a class=\"abstract\" href=\"UTD.htm?19/3/19514/abstract/58\">",
"     58",
"    </a>",
"    ]. In vitro data suggest that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/51/33584?source=see_link\">",
"     moxifloxacin",
"    </a>",
"    have greater activity against M. genitalium than tetracyclines [",
"    <a class=\"abstract\" href=\"UTD.htm?19/3/19514/abstract/59\">",
"     59",
"    </a>",
"    ]. Clinical trials comparing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    with azithromycin suggest significantly higher rates of eradication of M. genitalia with azithromycin, although overall cure rates are low (66 to 89 percent) compared with the desired cure rate for most STIs of 95 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?19/3/19514/abstract/60,61\">",
"     60,61",
"    </a>",
"    ]. The optimal agent, dose, and duration of treatment of M. genitalia are unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?19/3/19514/abstract/60,62,63\">",
"     60,62,63",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/13/40153?source=see_link\">",
"     \"Mycoplasma genitalium infection in men and women\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Trichomonas vaginalis is also known to cause urethritis in men, and empiric treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/14/5349?source=see_link\">",
"     tinidazole",
"    </a>",
"    should be provided if culture or NAATs for detection cannot be performed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/53/1881?source=see_link&amp;anchor=H13#H13\">",
"     \"Trichomonas vaginalis\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7889109\">",
"    <span class=\"h1\">",
"     PUBLIC HEALTH ISSUES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4144418\">",
"    <span class=\"h2\">",
"     Reporting",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United States, gonorrhea is reportable to public health authorities in every state and the District of Columbia; case reporting may be performed by the laboratory or provider.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4144433\">",
"    <span class=\"h2\">",
"     Management of sexual partners",
"    </span>",
"    &nbsp;&mdash;&nbsp;All individuals who have had sexual contact with patients diagnosed with N. gonorrhoeae within the past 60 days of the diagnosis should be evaluated and treated. If the patient&rsquo;s most recent sexual contact was greater than 60 days prior to diagnosis, the most recent sexual partner should be evaluated and treated. &nbsp;",
"   </p>",
"   <p>",
"    Sexual partners, particularly women, may be asymptomatic and, unless treated, will reinfect the index patient or spread infection to other partners. In the United States, the traditional approach has been to utilize members of a public health field team to notify exposed sex partners, but many health departments are no longer tracing these partners due to staffing shortages and lack of resources [",
"    <a class=\"abstract\" href=\"UTD.htm?19/3/19514/abstract/64\">",
"     64",
"    </a>",
"    ]. In lieu of public health advocacy, patients should be asked to notify their partners of the need for medical evaluation and treatment. Unfortunately, this approach is often inefficient [",
"    <a class=\"abstract\" href=\"UTD.htm?19/3/19514/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4146309\">",
"    <span class=\"h3\">",
"     Expedited partner therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Expedited partner therapy (EPT) is the clinical practice of treating the sex partners of patients diagnosed with sexually transmitted infections (STIs) without formal evaluation of the partner(s), by providing prescriptions or medications to the patient to deliver to the partner(s).",
"   </p>",
"   <p>",
"    Advocates for EPT cite its overall positive impact on reducing rates of reinfection and increasing the proportion of patients receiving therapeutic interventions [",
"    <a class=\"abstract\" href=\"UTD.htm?19/3/19514/abstract/65\">",
"     65",
"    </a>",
"    ]. In randomized trials, expedited partner therapy was more effective than traditional notification programs (ie, the patient notifies the partner of the need for evaluation and treatment) in reducing persistent or recurrent urogenital gonococcal infection among index patients [",
"    <a class=\"abstract\" href=\"UTD.htm?19/3/19514/abstract/66,67\">",
"     66,67",
"    </a>",
"    ]. However, limitations of this strategy include lost opportunities for",
"    <span class=\"nowrap\">",
"     STI/HIV",
"    </span>",
"    screening and risk of unmonitored adverse events related to antibiotic administration [",
"    <a class=\"abstract\" href=\"UTD.htm?19/3/19514/abstract/64,66\">",
"     64,66",
"    </a>",
"    ]. Furthermore, the preferred treatment regimen for gonorrhea is a parenteral and oral antibiotic combination that cannot be delivered using EPT.",
"   </p>",
"   <p>",
"    Given emerging resistance among gonococcal isolates, we are in agreement with the CDC which recommends avoiding EPT for gonorrhea, particularly among MSM since this group is at increased risk for coinfection with other STIs including undiagnosed HIV [",
"    <a class=\"abstract\" href=\"UTD.htm?19/3/19514/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?18/30/18914?source=see_link\">",
"       \"Patient information: Epididymitis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?1/44/1730?source=see_link\">",
"       \"Patient information: Gonorrhea (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7889919\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gonococcal infections, including urethritis, cervicitis, epididymitis, and proctitis, are a significant cause of morbidity among sexually active men and women. (See",
"      <a class=\"local\" href=\"#H7888990\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Since treatment failure for gonococcal eradication has significant public health implications, it is desirable for therapeutic regimens to have efficacy rates of greater than 95 percent. The selection of the treatment regimen must also include consideration of drug resistance and potential copathogens, such as Chlamydia trachomatis. (See",
"      <a class=\"local\" href=\"#H7888997\">",
"       'General background'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      High microbiologic cure rates of gonococcal infection had been documented for multiple classes of drugs in the past. However, surveillance of resistance patterns in N. gonorrhoeae worldwide have demonstrated increased resistance to multiple classes of antibiotics including penicillins, tetracyclines, macrolides and fluoroquinolones. Of the cephalosporin class of drugs,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"       ceftriaxone",
"      </a>",
"      has the lowest rates of gonococcal drug resistance in epidemiologic surveys. In addition, ceftriaxone cures approximately 98 to 99 percent of pharyngeal and uncomplicated urogenital and anorectal infections. (See",
"      <a class=\"local\" href=\"#H7889004\">",
"       'Antibiotic resistance'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H832751\">",
"       'Efficacy of ceftriaxone'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A low but increasing proportion of isolates with decreased susceptibility to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"       ceftriaxone",
"      </a>",
"      are being reported worldwide. Because of this trend and the lack of new, effective antimicrobials in advanced product development, we suggest dual rather than monotherapy for the treatment of gonococcal infections (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1115932\">",
"       'Rationale for dual therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For the treatment of suspected or confirmed uncomplicated urogenital gonococcal infection, we recommend",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"       ceftriaxone",
"      </a>",
"      as the first agent (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). For the second agent, we suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"       azithromycin",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       Doxycycline",
"      </a>",
"      is an alternate option. Ceftriaxone is administered as a single injection of a 250 mg dose at the point of care. Azithromycin is given orally as a single dose (1 g) while doxycycline is given twice daily for seven days (100 mg). Azithromycin and doxycycline also have activity against chlamydia, which is a common copathogen. (See",
"      <a class=\"local\" href=\"#H1115841\">",
"       'Approach to treatment'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/44/34505?source=see_link&amp;anchor=H5622559#H5622559\">",
"       \"Treatment of Chlamydia trachomatis infection\", section on 'Treatment of uncomplicated genital chlamydia infection'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pharyngeal infections may be somewhat more difficult to cure and may serve as an important reservoir of infection. (See",
"      <a class=\"local\" href=\"#H7889046\">",
"       'Pharyngeal infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pregnant women with uncomplicated gonorrheal infection should be treated with dual therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"       ceftriaxone",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"       azithromycin",
"      </a>",
"      since",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      should be avoided during pregnancy. (See",
"      <a class=\"local\" href=\"#H279639\">",
"       'Pregnant women'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The management of the penicillin allergic patient depends upon the clinical suspicion of true allergy and the type of the allergy (eg, morbilliform rash versus IgE-mediated reactions, such as urticaria). (See",
"      <a class=\"local\" href=\"#H279612\">",
"       'Penicillin allergic patients'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Persons diagnosed with a sexually transmitted infection are at high risk for HIV infection and should be offered testing. (See",
"      <a class=\"local\" href=\"#H4144118\">",
"       'HIV counseling and testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients who finish a recommended regimen for treatment of uncomplicated gonorrheal infections do not need to return for a test of cure. We perform a test of cure with culture, if available, seven days following therapy for any patient who receives an alternate regimen (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"       azithromycin",
"      </a>",
"      monotherapy or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/44/16070?source=see_link\">",
"       cefixime",
"      </a>",
"      -based regimen). Additionally, patients who continue to be symptomatic should be re-evaluated for treatment failure or other sexually transmitted infections. (See",
"      <a class=\"local\" href=\"#H22560004\">",
"       'Patient follow-up'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7889102\">",
"       'Postgonococcal urethritis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment of sexual partners is essential for preventing reinfection and controlling the spread of N. gonorrhoeae. For sex partners of patients with documented gonococcal infection, we suggest not routinely employing expedited partner therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Instead, we prefer evaluation and management through traditional strategies of public health or patient notification. However, if a heterosexual partner cannot be evaluated and managed in this manner, delivery of oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/44/16070?source=see_link\">",
"       cefixime",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"       azithromycin",
"      </a>",
"      through expedited partner therapy is a reasonable approach. (See",
"      <a class=\"local\" href=\"#H4144433\">",
"       'Management of sexual partners'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/3/19514/abstract/1\">",
"      Centers for Disease Control and Prevention (CDC). Update to CDC's Sexually transmitted diseases treatment guidelines, 2010: oral cephalosporins no longer a recommended treatment for gonococcal infections. MMWR Morb Mortal Wkly Rep 2012; 61:590.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.cdc.gov/std/treatment/2010/default.htm (Accessed on January 13, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/3/19514/abstract/3\">",
"      Workowski KA, Berman SM, Douglas JM Jr. Emerging antimicrobial resistance in Neisseria gonorrhoeae: urgent need to strengthen prevention strategies. Ann Intern Med 2008; 148:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/3/19514/abstract/4\">",
"      Newman LM, Moran JS, Workowski KA. Update on the management of gonorrhea in adults in the United States. Clin Infect Dis 2007; 44 Suppl 3:S84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/3/19514/abstract/5\">",
"      Moran JS, Levine WC. Drugs of choice for the treatment of uncomplicated gonococcal infections. Clin Infect Dis 1995; 20 Suppl 1:S47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/3/19514/abstract/6\">",
"      Datta SD, Sternberg M, Johnson RE, et al. Gonorrhea and chlamydia in the United States among persons 14 to 39 years of age, 1999 to 2002. Ann Intern Med 2007; 147:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/3/19514/abstract/7\">",
"      Gottlieb SL, Berman SM, Low N. Screening and treatment to prevent sequelae in women with Chlamydia trachomatis genital infection: how much do we know? J Infect Dis 2010; 201 Suppl 2:S156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/3/19514/abstract/8\">",
"      Ross JD, Lewis DA. Cephalosporin resistant Neisseria gonorrhoeae: time to consider gentamicin? Sex Transm Infect 2012; 88:6.",
"     </a>",
"    </li>",
"    <li>",
"     European Centre for Disease Prevention and Control. Gonococcal antimicrobial susceptibility surveillance in Europe - 2010. ECDC, Stockholm, 2012.",
"    </li>",
"    <li>",
"     Australian Gonococcal Surveillance Programme annual reports. file://www.health.gov.au/internet/main/publishing.nsf/content/cda-pubs-annlrpt-gonoanrep.htm (Accessed on June 12, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/3/19514/abstract/11\">",
"      Centers for Disease Control and Prevention (CDC). Update to CDC's sexually transmitted diseases treatment guidelines, 2006: fluoroquinolones no longer recommended for treatment of gonococcal infections. MMWR Morb Mortal Wkly Rep 2007; 56:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/3/19514/abstract/12\">",
"      Sparling PF. Antibiotic resistance in Neisseria gonorrhoeae. Med Clin North Am 1972; 56:1133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/3/19514/abstract/13\">",
"      Kirkcaldy RD, Zaidi A, Hook EW, et al. Neisseria gonorrhoeae Antimicrobial Resistance Among Men Who Have Sex With Men and Men Who Have Sex Exclusively With Women: The Gonococcal Isolate Surveillance Project, 2005-2010. Ann Intern Med 2013; 158:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/3/19514/abstract/14\">",
"      Schwarcz SK, Zenilman JM, Schnell D, et al. National surveillance of antimicrobial resistance in Neisseria gonorrhoeae. The Gonococcal Isolate Surveillance Project. JAMA 1990; 264:1413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/3/19514/abstract/15\">",
"      Centers for Disease Control and Prevention (CDC). Cephalosporin susceptibility among Neisseria gonorrhoeae isolates--United States, 2000-2010. MMWR Morb Mortal Wkly Rep 2011; 60:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/3/19514/abstract/16\">",
"      Muratani T, Akasaka S, Kobayashi T, et al. Outbreak of cefozopran (penicillin, oral cephems, and aztreonam)-resistant Neisseria gonorrhoeae in Japan. Antimicrob Agents Chemother 2001; 45:3603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/3/19514/abstract/17\">",
"      Yokoi S, Deguchi T, Ozawa T, et al. Threat to cefixime treatment for gonorrhea. Emerg Infect Dis 2007; 13:1275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/3/19514/abstract/18\">",
"      Barry PM, Klausner JD. The use of cephalosporins for gonorrhea: the impending problem of resistance. Expert Opin Pharmacother 2009; 10:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/3/19514/abstract/19\">",
"      Allen VG, Mitterni L, Seah C, et al. Neisseria gonorrhoeae treatment failure and susceptibility to cefixime in Toronto, Canada. JAMA 2013; 309:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/3/19514/abstract/20\">",
"      Chisholm SA, Mouton JW, Lewis DA, et al. Cephalosporin MIC creep among gonococci: time for a pharmacodynamic rethink? J Antimicrob Chemother 2010; 65:2141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/3/19514/abstract/21\">",
"      Martin I, Sawatzky P, Allen V, et al. Emergence and characterization of Neisseria gonorrhoeae isolates with decreased susceptibilities to ceftriaxone and cefixime in Canada: 2001-2010. Sex Transm Dis 2012; 39:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/3/19514/abstract/22\">",
"      Ray K, Bala M, Kumari S, Narain JP. Antimicrobial resistance of Neisseria gonorrhoeae in selected World Health Organization Southeast Asia Region countries: an overview. Sex Transm Dis 2005; 32:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/3/19514/abstract/23\">",
"      Starnino S, GASP-LAC Working Group, Galarza P, et al. Retrospective analysis of antimicrobial susceptibility trends (2000-2009) in Neisseria gonorrhoeae isolates from countries in Latin America and the Caribbean shows evolving resistance to ciprofloxacin, azithromycin and decreased susceptibility to ceftriaxone. Sex Transm Dis 2012; 39:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/3/19514/abstract/24\">",
"      Ohnishi M, Golparian D, Shimuta K, et al. Is Neisseria gonorrhoeae initiating a future era of untreatable gonorrhea?: detailed characterization of the first strain with high-level resistance to ceftriaxone. Antimicrob Agents Chemother 2011; 55:3538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/3/19514/abstract/25\">",
"      Ohnishi M, Saika T, Hoshina S, et al. Ceftriaxone-resistant Neisseria gonorrhoeae, Japan. Emerg Infect Dis 2011; 17:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/3/19514/abstract/26\">",
"      Unemo M, Golparian D, Nicholas R, et al. High-level cefixime- and ceftriaxone-resistant Neisseria gonorrhoeae in France: novel penA mosaic allele in a successful international clone causes treatment failure. Antimicrob Agents Chemother 2012; 56:1273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/3/19514/abstract/27\">",
"      Unemo M, Golparian D, Hestner A. Ceftriaxone treatment failure of pharyngeal gonorrhoea verified by international recommendations, Sweden, July 2010. Euro Surveill 2011; 16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/3/19514/abstract/28\">",
"      Bolan GA, Sparling PF, Wasserheit JN. The emerging threat of untreatable gonococcal infection. N Engl J Med 2012; 366:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/3/19514/abstract/29\">",
"      Whiley DM, Goire N, Lahra MM, et al. The ticking time bomb: escalating antibiotic resistance in Neisseria gonorrhoeae is a public health disaster in waiting. J Antimicrob Chemother 2012; 67:2059.",
"     </a>",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention (CDC). Sexually Transmitted Disease Surveillance, 2008. CDC; Department of Health and Human Services, Atlanta, GA 2009.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/3/19514/abstract/31\">",
"      Centers for Disease Control and Prevention (CDC). Neisseria gonorrhoeae with reduced susceptibility to azithromycin--San Diego County, California, 2009. MMWR Morb Mortal Wkly Rep 2011; 60:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/3/19514/abstract/32\">",
"      Katz AR, Komeya AY, Soge OO, et al. Neisseria gonorrhoeae with high-level resistance to azithromycin: case report of the first isolate identified in the United States. Clin Infect Dis 2012; 54:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/3/19514/abstract/33\">",
"      Yuan LF, Yin YP, Dai XQ, et al. Resistance to azithromycin of Neisseria gonorrhoeae isolates from 2 cities in China. Sex Transm Dis 2011; 38:764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/3/19514/abstract/34\">",
"      Lo JY, Ho KM, Lo AC. Surveillance of gonococcal antimicrobial susceptibility resulting in early detection of emerging resistance. J Antimicrob Chemother 2012; 67:1422.",
"     </a>",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. 2010 Sexually transmitted diseases surveillance - Gonorrhea. file://www.cdc.gov/std/stats10/gonorrhea.htm (Accessed on June 13, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/3/19514/abstract/36\">",
"      Cole MJ, Chisholm SA, Hoffmann S, et al. European surveillance of antimicrobial resistance in Neisseria gonorrhoeae. Sex Transm Infect 2010; 86:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/3/19514/abstract/37\">",
"      Boslego JW, Tramont EC, Takafuji ET, et al. Effect of spectinomycin use on the prevalence of spectinomycin-resistant and of penicillinase-producing Neisseria gonorrhoeae. N Engl J Med 1987; 317:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/3/19514/abstract/38\">",
"      Kunz AN, Begum AA, Wu H, et al. Impact of fluoroquinolone resistance mutations on gonococcal fitness and in vivo selection for compensatory mutations. J Infect Dis 2012; 205:1821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/3/19514/abstract/39\">",
"      Dillon JA, Parti RP. Fluoroquinolone resistance in Neisseria gonorrhoeae: fitness cost or benefit? J Infect Dis 2012; 205:1775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/3/19514/abstract/40\">",
"      Cohen MS. Sexually transmitted diseases enhance HIV transmission: no longer a hypothesis. Lancet 1998; 351 Suppl 3:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/3/19514/abstract/41\">",
"      Wang SA, Harvey AB, Conner SM, et al. Antimicrobial resistance for Neisseria gonorrhoeae in the United States, 1988 to 2003: the spread of fluoroquinolone resistance. Ann Intern Med 2007; 147:81.",
"     </a>",
"    </li>",
"    <li>",
"     British Association for Sexual Health and HIV. BASHH Clinical Effectiveness Group Guidelines. file://www.bashh.org/guidelines (Accessed on June 13, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/3/19514/abstract/43\">",
"      Bai ZG, Bao XJ, Cheng WD, et al. Efficacy and safety of ceftriaxone for uncomplicated gonorrhoea: a meta-analysis of randomized controlled trials. Int J STD AIDS 2012; 23:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/3/19514/abstract/44\">",
"      Moran JS. Treating uncomplicated Neisseria gonorrhoeae infections: is the anatomic site of infection important? Sex Transm Dis 1995; 22:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/3/19514/abstract/45\">",
"      Handsfield HH, McCormack WM, Hook EW 3rd, et al. A comparison of single-dose cefixime with ceftriaxone as treatment for uncomplicated gonorrhea. The Gonorrhea Treatment Study Group. N Engl J Med 1991; 325:1337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/3/19514/abstract/46\">",
"      Ison CA, Mouton JW, Jones K, et al. Which cephalosporin for gonorrhoea? Sex Transm Infect 2004; 80:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/3/19514/abstract/47\">",
"      Pandori M, Barry PM, Wu A, et al. Mosaic penicillin-binding protein 2 in Neisseria gonorrhoeae isolates collected in 2008 in San Francisco, California. Antimicrob Agents Chemother 2009; 53:4032.",
"     </a>",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention (CDC). Gonococcal Isolate Surveillance Project (GISP) annual report &mdash; 2004. CDC; Department of Health and Human Services, Atlanta, GA 2005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/3/19514/abstract/49\">",
"      Bignell C, Garley J. Azithromycin in the treatment of infection with Neisseria gonorrhoeae. Sex Transm Infect 2010; 86:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/3/19514/abstract/50\">",
"      Handsfield HH, Dalu ZA, Martin DH, et al. Multicenter trial of single-dose azithromycin vs. ceftriaxone in the treatment of uncomplicated gonorrhea. Azithromycin Gonorrhea Study Group. Sex Transm Dis 1994; 21:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/3/19514/abstract/51\">",
"      Centers for Disease Control and Prevention. Notice to readers: Discontinuation of spectinomycin. MMWR Morb Mortal Wkly Rep 2006; 55:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/3/19514/abstract/52\">",
"      Weinstock H, Workowski KA. Pharyngeal gonorrhea: an important reservoir of infection? Clin Infect Dis 2009; 49:1798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/3/19514/abstract/53\">",
"      Haimovici R, Roussel TJ. Treatment of gonococcal conjunctivitis with single-dose intramuscular ceftriaxone. Am J Ophthalmol 1989; 107:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/3/19514/abstract/54\">",
"      Trojian TH, Lishnak TS, Heiman D. Epididymitis and orchitis: an overview. Am Fam Physician 2009; 79:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/3/19514/abstract/55\">",
"      Schwarcz S, Weinstock H, Louie B, et al. Characteristics of persons with recently acquired HIV infection: application of the serologic testing algorithm for recent HIV seroconversion in 10 US cities. J Acquir Immune Defic Syndr 2007; 44:112.",
"     </a>",
"    </li>",
"    <li>",
"     CDC Dear Colleague letter regarding azithromycin resistance in N. gonorrhoeae. file://www.cdc.gov/std/gonorrhea/DCL-Azithro-GC-May-24-2011.pdf (Accessed on June 19, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/3/19514/abstract/57\">",
"      Yokoi S, Maeda S, Kubota Y, et al. The role of Mycoplasma genitalium and Ureaplasma urealyticum biovar 2 in postgonococcal urethritis. Clin Infect Dis 2007; 45:866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/3/19514/abstract/58\">",
"      Mobley VL, Hobbs MM, Lau K, et al. Mycoplasma genitalium infection in women attending a sexually transmitted infection clinic: diagnostic specimen type, coinfections, and predictors. Sex Transm Dis 2012; 39:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/3/19514/abstract/59\">",
"      Hamasuna R, Osada Y, Jensen JS. Antibiotic susceptibility testing of Mycoplasma genitalium by TaqMan 5' nuclease real-time PCR. Antimicrob Agents Chemother 2005; 49:4993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/3/19514/abstract/60\">",
"      Mena LA, Mroczkowski TF, Nsuami M, Martin DH. A randomized comparison of azithromycin and doxycycline for the treatment of Mycoplasma genitalium-positive urethritis in men. Clin Infect Dis 2009; 48:1649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/3/19514/abstract/61\">",
"      Schwebke JR, Rompalo A, Taylor S, et al. Re-evaluating the treatment of nongonococcal urethritis: emphasizing emerging pathogens--a randomized clinical trial. Clin Infect Dis 2011; 52:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/3/19514/abstract/62\">",
"      Bradshaw CS, Chen MY, Fairley CK. Persistence of Mycoplasma genitalium following azithromycin therapy. PLoS One 2008; 3:e3618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/3/19514/abstract/63\">",
"      Bj&ouml;rnelius E, Anagrius C, Bojs G, et al. Antibiotic treatment of symptomatic Mycoplasma genitalium infection in Scandinavia: a controlled clinical trial. Sex Transm Infect 2008; 84:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/3/19514/abstract/64\">",
"      Erbelding EJ, Zenilman JM. Toward better control of sexually transmitted diseases. N Engl J Med 2005; 352:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/3/19514/abstract/65\">",
"      Golden MR. Expedited partner therapy for sexually transmitted diseases. Clin Infect Dis 2005; 41:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/3/19514/abstract/66\">",
"      Golden MR, Whittington WL, Handsfield HH, et al. Effect of expedited treatment of sex partners on recurrent or persistent gonorrhea or chlamydial infection. N Engl J Med 2005; 352:676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/3/19514/abstract/67\">",
"      Kissinger P, Mohammed H, Richardson-Alston G, et al. Patient-delivered partner treatment for male urethritis: a randomized, controlled trial. Clin Infect Dis 2005; 41:623.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.cdc.gov/std/ept/GC-Guidance.htm (Accessed on April 01, 2013).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15892 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-6ED53622C5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_3_19514=[""].join("\n");
var outline_f19_3_19514=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H7889919\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7888990\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7888997\">",
"      GENERAL BACKGROUND",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1115797\">",
"      Therapeutic principles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1115804\">",
"      Chlamydia as a copathogen",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7889004\">",
"      ANTIBIOTIC RESISTANCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H77502526\">",
"      Cephalosporins",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H365932\">",
"      - Cefixime",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H365939\">",
"      - Ceftriaxone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H77502541\">",
"      Azithromycin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H366617\">",
"      Tetracycline",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H366145\">",
"      Aminoglycosides",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H77502534\">",
"      Fluoroquinolones",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1115841\">",
"      APPROACH TO TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H278540\">",
"      Preferred regimen for urogenital infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H832751\">",
"      - Efficacy of ceftriaxone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1116052\">",
"      - Changes in dosing of ceftriaxone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1115932\">",
"      - Rationale for dual therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7889039\">",
"      Alternate therapies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H195635372\">",
"      - Other cephalosporins",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H195635379\">",
"      - Azithromycin monotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H195635386\">",
"      - Spectinomycin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1117033\">",
"      Other gonococcal infections",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7889046\">",
"      - Pharyngeal infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7889060\">",
"      - Conjunctivitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7889074\">",
"      - Epididymitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7889081\">",
"      - Proctitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1117152\">",
"      - Pelvic inflammatory disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14405271\">",
"      - Disseminated gonococcal infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H279604\">",
"      Specific populations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H279612\">",
"      - Penicillin allergic patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H279639\">",
"      - Pregnant women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4144011\">",
"      PATIENT COUNSELING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4144073\">",
"      Sexual activity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4144118\">",
"      HIV counseling and testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4144362\">",
"      Pregnancy testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22560004\">",
"      PATIENT FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22560034\">",
"      Test of cure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2836827\">",
"      Monitoring for treatment failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22560061\">",
"      Retesting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7889102\">",
"      POSTGONOCOCCAL URETHRITIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7889109\">",
"      PUBLIC HEALTH ISSUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4144418\">",
"      Reporting",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4144433\">",
"      Management of sexual partners",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4146309\">",
"      - Expedited partner therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7889919\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/15892\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/15892|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?25/10/25760\" title=\"algorithm 1\">",
"      Admin of a cephalosporin to a patient with a hx of PCN allergy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/46/23274?source=related_link\">",
"      Allergy to penicillins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/17/20760?source=related_link\">",
"      Conjunctivitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/38/29286?source=related_link\">",
"      Cutaneous manifestations of gonorrhea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/35/26166?source=related_link\">",
"      Diagnosis of gonococcal infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20345?source=related_link\">",
"      Diagnostic assays for HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/56/3976?source=related_link\">",
"      Disseminated gonococcal infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/20/38217?source=related_link\">",
"      Epidemiology, pathogenesis, and clinical manifestations of Neisseria gonorrhoeae infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/20/44360?source=related_link\">",
"      Evaluation of the acute scrotum in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/18/18728?source=related_link\">",
"      Genital Chlamydia trachomatis infections in men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/46/42728?source=related_link\">",
"      Genital Chlamydia trachomatis infections in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/13/40153?source=related_link\">",
"      Mycoplasma genitalium infection in men and women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?18/30/18914?source=related_link\">",
"      Patient information: Epididymitis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?1/44/1730?source=related_link\">",
"      Patient information: Gonorrhea (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/19/15672?source=related_link\">",
"      Penicillin-allergic patients: Use of cephalosporins, carbapenems, and monobactams",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/12/35018?source=related_link\">",
"      Prevention of sexually transmitted infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/62/29672?source=related_link\">",
"      Rapid drug desensitization for immediate hypersensitivity reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/34/10793?source=related_link\">",
"      Serologic screening for HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/44/34505?source=related_link\">",
"      Treatment of Chlamydia trachomatis infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/63/35832?source=related_link\">",
"      Treatment of pelvic inflammatory disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/53/1881?source=related_link\">",
"      Trichomonas vaginalis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_3_19515="HAT characteristics";
var content_f19_3_19515=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F86456&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=11\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F86456&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=11\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Characteristics of African trypanosomiasis species",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"3\" width=\"33%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        T. b. gambiense",
"       </td>",
"       <td class=\"subtitle1\">",
"        T. b. rhodesiense",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Geographic distribution",
"        </strong>",
"       </td>",
"       <td>",
"        West, Central Africa",
"       </td>",
"       <td>",
"        East Africa",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Fly species",
"        </strong>",
"       </td>",
"       <td>",
"        Glossina palpalis",
"       </td>",
"       <td>",
"        Glossina morsitans",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Fly habitat",
"        </strong>",
"       </td>",
"       <td>",
"        Humid; river habitat",
"       </td>",
"       <td>",
"        Dry; savannah and woodland habitat",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Primary host",
"        </strong>",
"       </td>",
"       <td>",
"        Humans",
"       </td>",
"       <td>",
"        Animals",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Nature of clinical infection",
"        </strong>",
"       </td>",
"       <td>",
"        Chronic",
"       </td>",
"       <td>",
"        Acute",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_3_19515=[""].join("\n");
var outline_f19_3_19515=null;
var title_f19_3_19516="Features CVS children";
var content_f19_3_19516=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F62483&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F62483&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical/epidemiological features of cyclic vomiting syndrome",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Feature",
"       </td>",
"       <td class=\"subtitle1\">",
"        Characterization",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Female:male ratio",
"       </td>",
"       <td>",
"        55:45",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Age of onset",
"       </td>",
"       <td>",
"        5.3 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Morbidity",
"       </td>",
"       <td>",
"        20 days of missed school per year, 50 percent of patients require intravenous hydration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"2\">",
"        Symptoms:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Vomiting",
"       </td>",
"       <td class=\"sublist_other\">",
"        6 times/hr at peak, with bile (76 percent) and blood (32 percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Autonomic",
"       </td>",
"       <td class=\"sublist_other\">",
"        Lethargy (91 percent), pallor (87 percent), fever (29 percent), salivation (13 percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Gastrointestinal",
"       </td>",
"       <td class=\"sublist_other\">",
"        Abdominal pain (80 percent), retching (78 percent), anorexia (74 percent), nausea (72 percent), diarrhea (36 percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Neurologic",
"       </td>",
"       <td class=\"sublist_other\">",
"        Headache (40 percent), photophobia (32 percent), phonophobia (28 percent), vertigo (22 percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Temporal pattern",
"       </td>",
"       <td>",
"        24 to 48 hours duration; 47 percent of patients have episodes at regular intervals, usually two to four weeks; episodes occur at night or early morning in 34 to 60 percent of patients; 98 percent of patients show a stereotypical pattern",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Precipitating events",
"       </td>",
"       <td>",
"        Infection (41 percent), psychological stress (34 percent), dietary (26 percent), menstrual (13 percent), some trigger identified in 68 percent of patients",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Natural history",
"       </td>",
"       <td>",
"        3.4 year duration; 28 percent of patients progress to migraine headaches; predicted 75 percent progress to migraines by age 18 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Family history of migraine",
"       </td>",
"       <td>",
"        Present in 82 percent of patients",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Li BU, Balint JP. Cyclic vomiting syndrome: Evolution in understanding of a brain-gut disorder. Adv Pediatr 2000; 47:117 and Li BU. Cyclic vomiting: New understanding of an old disorder. Contemp Pediatr 1996; 17:48.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_3_19516=[""].join("\n");
var outline_f19_3_19516=null;
var title_f19_3_19517="Topical antifungal agents";
var content_f19_3_19517=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F76148&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F76148&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Topical antifungal agents",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Drug",
"      </td>",
"      <td class=\"subtitle1\">",
"       Dose",
"      </td>",
"      <td class=\"subtitle1\">",
"       How supplied",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"3\">",
"       Azoles: Indicated for dermatophytes, tinea versicolor, and Candida",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\" colspan=\"1\" rowspan=\"3\">",
"       Clotrimazole (Lotrimin)*",
"      </td>",
"      <td colspan=\"1\" rowspan=\"3\">",
"       BID",
"      </td>",
"      <td>",
"       Cream 1%: 15 g, 30 g, 45 g, 90 g",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Lotion 1%: 30 mL",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Solution 1%: 10 mL, 30 mL",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Econazole (Spectazole)",
"      </td>",
"      <td>",
"       QD (BID for candidiasis)",
"      </td>",
"      <td>",
"       Cream 1%: 15 g, 30 g, 85 g",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Ketoconazole (Nizoral)",
"      </td>",
"      <td>",
"       QD",
"      </td>",
"      <td>",
"       Cream 2%: 15 g, 30 g, 60 g",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Miconazole (Monistat-Derm)*",
"      </td>",
"      <td>",
"       BID",
"      </td>",
"      <td>",
"       Cream 2%: 15 g, 30 g, 56.7 g, 85 g",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\" colspan=\"1\" rowspan=\"2\">",
"       Oxiconazole (Oxistat)",
"      </td>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       QD to BID",
"      </td>",
"      <td>",
"       Cream 1%: 15 g, 30 g, 60 g",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Lotion 1%: 30 mL",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Sertaconazole (Ertaczo)",
"      </td>",
"      <td>",
"       BID",
"      </td>",
"      <td>",
"       Cream 2%: 30 g",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\" colspan=\"1\" rowspan=\"2\">",
"       Sulconazole (Exelderm)",
"      </td>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       QD to BID",
"      </td>",
"      <td>",
"       Cream 1%: 15 g, 30 g, 60 g",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Solution 1%: 30 mL",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"3\">",
"       Allylamines: Indicated for dermatophytes and tinea versicolor&bull;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\" colspan=\"1\" rowspan=\"2\">",
"       Naftifine (Naftin)",
"      </td>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       QD (cream), BID (gel)",
"      </td>",
"      <td>",
"       Cream 1%: 15 g, 30 g, 60 g",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Gel 1%: 20 g, 40 g, 60 g",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\" colspan=\"1\" rowspan=\"3\">",
"       Terbinafine (Lamisil AT)",
"      </td>",
"      <td colspan=\"1\" rowspan=\"3\">",
"       QD to BID",
"      </td>",
"      <td>",
"       Cream 1%: 15 g, 30 g",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Gel 1%: 5 g, 15 g, 30 g",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Spray solution 1%: 30 mL",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"3\">",
"       Benzylamine: Indicated for dermatophytes and tinea versicolor&bull;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Butenafine (Mentax, Lotrimin Ultra)*",
"      </td>",
"      <td>",
"       QD (BID for tinea pedis)",
"      </td>",
"      <td>",
"       Cream 1%: 12 g, 15 g, 24 g, 30 g",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"3\">",
"       Polyene: Treats Candida infections only",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\" rowspan=\"3\">",
"       Nystatin",
"      </td>",
"      <td rowspan=\"3\">",
"       BID",
"      </td>",
"      <td>",
"       Cream: 15 g, 30 g",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Ointment: 15 g, 30 g",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Powder: 15 g, 30 g, 60 g",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"3\">",
"       Other",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\" colspan=\"1\" rowspan=\"3\">",
"       Ciclopirox (Loprox)&Delta;",
"      </td>",
"      <td colspan=\"1\" rowspan=\"3\">",
"       BID",
"      </td>",
"      <td>",
"       Cream 1%: 15 g, 30 g, 90 g",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Lotion 1%: 30 mL, 60 mL",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Topical suspension 0.77%: 30 mL, 60 mL",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\" colspan=\"1\" rowspan=\"7\">",
"       Tolnaftate (Tinactin)*&loz;",
"      </td>",
"      <td colspan=\"1\" rowspan=\"7\">",
"       BID",
"      </td>",
"      <td>",
"       Cream 1%: 15 g, 30 g",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Gel 1%: 15 g",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Powder 1%: 45 g, 90 g",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Topical aerosol:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       liquid (1%): 59.2 mL, 90 mL, 120 mL",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       powder (1%): 56.7 g, 100 g, 105 g, 150 g",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Solution 1%: 10 mL",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     QD: daily; BID: twice daily; %: percent. Brand names provided are examples, other products may also be available.",
"     <br>",
"      * Also available in over the counter preparations.",
"      <br>",
"       &bull; Can also treat Candida, but may be less effective than azoles and ciclopirox.",
"       <br>",
"        &Delta; Treats dermatophytes, tinea versicolor, and Candida.",
"        <br>",
"         &loz; Does not treat Candida; less effective than other options for dermatophytes.",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_3_19517=[""].join("\n");
var outline_f19_3_19517=null;
var title_f19_3_19518="Nipple discharge algorithm";
var content_f19_3_19518=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F54471&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F54471&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Algorithm for management of spontaneous nipple discharge (non-lactating)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 366px; height: 392px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Breast ultrasound is recommended for imaging all patients with nipple discharge. Mammograms are recommended for women &ge; age 30.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: CRICO/RMF Breast care management algorithm www.rmf.harvard.edu/bca.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_3_19518=[""].join("\n");
var outline_f19_3_19518=null;
var title_f19_3_19519="Systolic BP cardiovascular death HOT trial";
var content_f19_3_19519=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F75482%7ENEPH%2F71321&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F75482%7ENEPH%2F71321&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Systolic pressure and cardiovascular mortality in HOT trial",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 384px; height: 332px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Estimated incidence (95 percent CI) of cardiovascular mortality in relation to achieved mean systolic blood pressure in the HOT trial. The systolic pressure at the lowest point of the curve is indicated (minimum).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Hansson L, Zanchetti A, Carruthers SG, et al. Lancet 1998; 351:1755.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Diastolic pressure and cardiovascular mortality in HOT trial",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 380px; height: 336px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Estimated incidence (95 percent CI) of cardiovascular mortality in relation to achieved mean diastolic blood pressure in the HOT trial. The diastolic pressure at the lowest point of the curve is indicated (minimum).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Hansson L, Zanchetti A, Carruthers SG, et al. Lancet 1998; 351:1755.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_3_19519=[""].join("\n");
var outline_f19_3_19519=null;
